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Chapter 1 
Introduction 
  
 
Part I. Cell Death Induced during Parvovirus Infection 
 
Introduction 
Parvoviruses have a nonenveloped icosahedral virion with a diameter of approximately 
20-25 nm, which encapsidates a linear, single-stranded DNA (ssDNA) genome of an average 
size of 5,000 bases (105). The family Parvoviridae contains two subfamilies: Parvovirinae and 
Densovirinae. The latter infects only invertebrates and will not be the subject of this review. The 
family Parvovirinae is composed of five genera: Amdovirus, Bocavirus, Dependovirus, 
Erytharovirus and Parvovirus  (102). Adeno-associated viruses (AAVs) in the genus 
Dependovirus require helper viruses (e.g., adenoviruses) for productive infection (13). All other 
members of Parvovirinae do not require helper virus and are called autonomous parvoviruses. 
In this review, the term “parvovirus” refers to viruses in the subfamily Parvovirinae.  
Disease outcomes of parvovirus infection vary among members of Parvovirinae. Human 
parvovirus B19 (B19V) is the only member that has been confirmed to be pathogenic to humans 
(227). B19V infection is the cause of an increasing list of diseases, including fifth disease in 
children, transient aplastic crisis in patients with chronic hemolytic anemia (e.g., sickle cell 
disease patients); pure red-cell aplasia in persistent infection in immunocompromised patients; 
and hydrops fetalis in pregnant women  (30, 57, 78, 192, 227). Human bocavirus (HBoV), which 
was identified in 2005, has been linked to lower respiratory tract infections in children (5, 8, 99) 
and was is associated with severe pneumonia in children coinfected with other respiratory 
viruses (98, 121). Of animal parvoviruses, Aleutian mink disease virus (AMDV), the only 
member in genus Amdovirus, causes the main symptoms of gastroenteritis, aplastic anemia and 
lymphopenia (17). In the genus Bocavirus, minute virus of canines (MVC) causes respiratory 
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diseases with breathing difficulty, enteritis with severe diarrhea, spontaneous abortion of fetuses 
and death of newborn pups (33, 86, 91). A similar enteritis was also seen in bovine parvovirus 
(BPV)-infected calves (67, 120). In the genus Parvovirus, infection of feline parvovirus (FPV) 
and canine parvovirus (CPV) causes gastrointestinal disease, e.g., enteritis (166-168). Porcine 
parvovirus was identified as the cause of stillborn and mummified piglets (215).  
The cytopathic effects (CPEs) induced during parvovirus infection have been widely 
documented. The disease outcomes of parvovirus infection are often the result of CPEs, e.g., 
cell death of B19V-infected erythroid progenitor cells causes anemia and non-immune hydrops 
fetalis (6, 29). Cell death induced during parvovirus infection appears to be mediated either by 
apoptosis or by necrosis (non-apoptotic cell death), whereas cell cycle arrest is often observed 
as one of the early responses of host cells to parvovirus infection.  
Apoptosis and necrosis are two types of cell death tightly controlled by distinct 
programmed signaling cascades. Apoptosis is divided mechanistically into two major pathways, 
i.e., extrinsic and intrinsic, both involving sequential activation of caspases. The extrinsic 
pathway is activated by the ligation of “death” ligands, such as Fas ligand and tumor necrosis 
factor-alpha (TNFα) to “death” receptors, followed by activation of caspase-8/caspase-10 and a 
cascade of caspase activation, which eventually leads to apoptosis (9). The mitochondrion-
mediated (intrinsic) pathway is activated by multidomain Bcl-2 family proteins, notably Bax and 
Bak (43, 159). This pathway causes mitochondrial outer membrane permeabilization (MOMP), 
resulting in the release of cytochrome c, Smac and Omi into cytosol, where they work with 
apoptotic protease-activating factor (Apaf-1) to form the apoptosome complex, followed by the 
activation of capase-9 and eventually apoptosis (111). Caspase-3, -6 and -7 are the 
downstream executor caspases (40). In addition, crosstalk between the extrinsic and intrinsic 
pathways has been well established (11, 186), e.g., activated caspase-8/10 cleaves Bid to tBid, 
which in turn activates Bax/Bak.  
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Necrosis, the catastrophic cell death, is characterized by organelle swelling, 
mitochondrial membrane dysfunction, massive oxidative stress and rapid plasma-membrane 
permeabilization (62). Previously, necrosis was thought to be un-regulated cell death; however, 
recently, a number of regulated non-apoptotic cell death pathways have been attributed to 
necrosis (108).  
Cell cycle check points are cellular mechanisms that ensure each and every step of the 
replication cycle takes place accurately and precisely at the right time. Each cell cycle check 
point is controlled by different cyclins and cyclin dependent kinases (CDKs) (93, 139). An 
aberrant cellular environment change or exogenous assault results in cell cycle check point 
arrest, which provides time for the cells to recover and return to their normal status before 
proceeding to the next step of the cell cycle (26).  
 
Human parvovirus B19 
B19V infection has an exclusive tropism for both CD36+ human erythroid progenitors 
and erythroblasts of the human bone marrow and fetal liver (132, 163, 199, 225). Clinical 
symptoms, as seen in anemia and non-immune hydrops fetalis, are the direct result of the 
destruction of erythroid progenitors in bone marrow and fetal tissues by virus infection (6, 29). 
Tissue samples from hydrops fetalis patients infected with B19V have been found to have 
characteristics of apoptosis (225). Fetal erythroid progenitors infected by B19V reveal 
ultrastructural features of apoptotic cell death (132). 
In vitro studies of B19V infection induced CPE have long been hampered by the lack of 
a permissive culture system. The first productive in vitro culture of B19V, reported in 1987, used 
bone marrow cells directly collected from a sickle cell patient (162). The establishment of a 
B19V semi-permissive cell line UT7/Epo-S1, a subclone of megakaryoblastic cell line UT7/Epo 
(135), allowed study of the role of viral non-structural proteins in B19V infection-induced cell 
death (131). The parent UT7/Epo cells only showed very limited permissiveness to B19V 
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infection (193). Ex vivo expanded erythroid progenitor cells have made it possible to carefully 
examine the cell death induced during B19V infection (38, 195, 222). 
 B19V infection of human bone marrow has been shown to inhibit both burst-forming 
erythroid unit (BFU-E) and cloning-forming erythroid unit (CFU-E), an arrest of erythropoiesis 
(163, 199). Previously, the cytotoxicity of B19V infection was believed to be a direct function of 
NS1 expression (161). The molecular mechanisms leading to apoptosis during B19V infection of 
primary erythroid progenitor cells was investigated in parallel with inducible stable NS1 
expression in UT7/Epo cells (195). Both B19V infection in erythroid progenitor cells and NS1-
induced apoptosis were inhibited by caspase-3, -6, and -8 inhibitors. Substantial caspase -3, -6, 
and -8 activities were induced by NS1 expression in UT7/Epo cells (195). The caspase-
mediated apoptosis by NS1 expression in UT7/Epo cells was evidenced by cell morphology, 
genomic DNA fragmentation (131) and stable expression of Bcl-2, an anti-apoptotic protein, 
which resulted in near-total protection from cell death in response to NS1 induction (131).  
Caspase-8, which mediates the extrinsic apoptotic pathway, was activated during B19V- and 
NS1-induced apoptosis. Consequently, B19V-infected erythroid progenitors and NS1-
expressing UT7/Epo cells were sensitized to TNFα-induced apoptosis (195). Moreover, the 
ceramide level was enhanced by B19V infection and NS1 expression. Therefore, a connection 
between the apoptotic pathways activated by TNFα and NS1 in B19V-infected human erythroid 
progenitor cells was proposed.      
B19V NS1 has been shown to induce apoptosis in non-permissive cell lines as well (89, 
131, 171). In addition, expressing NS1-transgene in mice under the erythroid lineage-specific 
GATA-1 promoter was demonstrated to be embryonic lethal as a result of fatal anemia (44). In 
non-permissive liver-derived cell types, both B19V inoculation and NS1 expression were shown 
to activate caspase-3 and -9, but not caspase-8 (171, 172). Treatment of transfected cells with 
inhibitors of caspase-3 or -9 significantly inhibited apoptosis. Neutralization of TNFα or Fas 
ligand had no effect on apoptosis induced in liver cells. In monkey epithelial cells COS-7, 
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expression of NS1 induced an increased level of apoptosis (89). Consistent with the results from 
liver cells, the increased expression of p53, the pro-apoptotic Bcl-2 members Bax, Bad and 
activation of caspase-3 and caspase-9, but not the activation of caspase-8 or Fas, were 
detected in the NS1-transfected cells. Furthermore, a p53 inhibitor abolished activation of 
caspase-9 and apoptosis was significantly diminished by the caspase-9 inhibitor (89). Thus, 
NS1 appears to induce intrinsic mitochondrion-mediated apoptosis in non-permissive cells. 
The B19V NS1 protein is a multifunctional protein during the virus life cycle (65, 76, 130, 
178, 196). Loss-of-function mutations engineered into the nucleoside triphosphate (NTP)-
binding domain of NS1 significantly rescued cells from NS1-induced apoptosis without having 
any effect on NS1-induced activation of IL-6 gene expression, which is mediated by NF-κB 
(131). Furthermore, using pentoxifylline, an inhibitor of NF-κB activation, the NF-κB-mediated IL-
6 activation by NS1 was shown to be uncoupled from the apoptotic pathway. Thus, induction of 
apoptosis by NS1, at least in UT-7/Epo-S1 cells, is a separate function from trans-activation. 
The loss-of-function mutation of the NTP-binding site of NS1 also significantly decreased 
apoptosis in HepG2 cells (171). Therefore, the NTP-binding motif of the B19V NS1 is required 
for NS1-induced apoptosis in both B19V semi-permissive and non-permissive cell lines.   
Overall, B19V NS1 induced apoptosis is characterized by caspase activation and DNA 
fragmentation. The extrinsic pathway, TNFα-induced activation of this pathway in particular, is 
thought to be responsible for NS1-induced apoptosis in permissive cells; while in non-
permissive cells, the mitochondrion-mediated intrinsic pathway is activated. Nevertheless, the 
NTP-binding motif of NS1 is the only domain identified to be required for inducing apoptosis in 
both permissive and non-permissive cells. Based on above evidence, NS1 has long been 
thought to be the only viral protein of B19V that induces apoptosis during B19V infection. 
However, the NS1-induced apoptosis could be exaggerated in both non-permissive and semi-
permissive cells as the kinetics of NS1 expression does not correlate with that of induction of 
apoptosis during B19V infection (134). 
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Using CD36+ erythroid progenitor cells ex vivo expanded from primary CD34+ 
hematopoietic stem cells (222), we have identified that the B19V small nonstructural protein 
11kDa as a novel inducer of apoptosis during B19V infection, which is mediated through 
caspase-10 activation (Chapter 2) (38). The 11kDa is expressed predominantly in the cytoplasm 
during B19V infection at a level at least 100 times more than NS1, which is solely expressed in 
the nucleus during the course of infection in CD36+ erythroid progenitor cells. By further knock-
down of 11kDa expression using antisense oligos, we confirmed that the 11kDa plays a key role 
in killing CD36+ erythroid progenitor cells during B19V infection. Interestingly, 11kDa was 
reported to interact with growth factor receptor-bound protein 2 (Grb2) via the SH3 domain 
binding motif in vitro (71). The mechanism underlying B19V 11kDa induced apoptosis, and 
especially the potential significance of the 11kDa-Grb2 interaction warrants further investigation.  
The G2/M cell cycle arrest induced during B19V infection is observed in both primary 
CD36+ erythroid progenitor cells(195) and the cell line UT7/Epo-S1 (135). In UT7/Epo-S1 cells, 
B19V infection induced an accumulation of cyclin A, cyclin B1, and phosphorylated cdc2 and 
was accompanied by an up-regulation in the kinase activity of the cdc2-cyclin B1 complex, 
which is consistent with G2/M check point arrest (135). In concert, degradation of nuclear 
lamina and phosphorylation of histone H3 and H1, markers of M-phase, were not seen in B19V-
infected cells. Moreover, accumulation of cyclin B1 was persistently localized in the cytoplasm, 
but not in the nucleus, suggesting that B19V infection contributes to the suppression of the 
nuclear import of cyclin B1.  
G0/G1 arrest was also demonstrated in B19V-infected UT7/Epo-S1 cells with application 
of the mitotic inhibitor paclitaxel (133). NS1-expressing UT7/Epo-S1 and 293T cells were shown 
to undergo ell cycle arrest at G0/G1 rather than G2/M check point. NS1 expression significantly 
increased p21WAF1 expression, a cyclin-dependent kinase inhibitor that induces G0/G1 arrest. In 
addition, G0/G1 arrest mediated by NS1 was proposed to be a prerequisite for the apoptosis of 
erythroid progenitor cells during B19 virus infection. In monkey epithelial cells COS-7, 
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expression of NS1 also induced G0/G1 check point arrest, accompanied by an increased level 
of apoptosis (89). The expression of p53 and its downstream cell cycle kinase inhibitors p16INK4 
and p21WAF1 were up-regulated in the NS1-transfected cells. Given the requirement of S-phase 
for the replication of parvoviruses, the role of NS1-induced G0/G1 arrest in the B19V life cell 
cycle needs to be clarified.  
G2/M arrest appears to be important for B19V infection, as inhibition of G2/M arrest by 
caffeine significantly decreased the expression of NS1 (133). However, the mechanism 
underlying B19V infection-induced G2/M cell cycle arrest, especially which viral components are 
involved, was uncertain. In our recent work, we found that the cell cycle arrest occurred as one 
of the earliest events during infection (134) (Chen AY & Qiu J, unpublished data). While UV-
inactivated B19V did not express NS1, it induced G2/M arrest at a level similar to that induced 
by the infectious virus (133), indicating that the viral genome might paly an improtant role in the 
cells cycel arrest. Expression of B19V viral proteins (NS1, VP1, VP2, 11kDa and 7.5kDa) in 
UT7/Epo-S1 cells by transfection did not change the cell cycle pattern. However, transfection of 
a viral sequence containing half of the left hand inverted terminal repeat did partially produce a 
G2/M arrest (Chen AY & Qiu J, unpublished data). Only recently, a CpG oligodeoxynucleotide 
2006, containing a consensus sequence located in the P6-promoter region of B19V genome (5'-
GTTTTGT-3'), directly inhibited the growth of burst-forming erythroid (BFU-E) cells, resulting in 
the accumulation of cells in the S and G2/M phases and increased cell size and frequency of 
apoptotic cells (83). Therefore, the B19V viral genome seems to play an important role in 
arresting the cell cycle at G2/M.  
Overall, apoptosis is the programmed cell death pathway underlying B19V infection of 
erythroid progenitors. Viral proteins, NS1 and 11kDa in particular, are responsible for promoting 
the apoptotic process; however, the 11kDa protein is likely the major apoptotic inducer, 
considering it is expressed at a level 100 times more than that of NS1 during B19V infection. 
Other to-be-identified factors, such as the viral genome and the 7.5kDa small nonstructural 
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protein, may also contribute to ensure the cell death outcome. G2/M cell cycle arrest by the 
B19V genome occurs early during infection and may contribute to the CPE during the early 
phase of B19V infection. Though the underlying mechanism is largely unknown, a viral genome-
induced, DNA damage response-mediated pathway is likely involved.   
 
Amdovirus 
AMDV is the first parvovirus known to utilize caspase activity to facilitate its replication 
(16, 17). AMDV infection induces caspase activation and result in apoptotic cell death (17). 
Pretreatment of infected cells with caspase-3 or broad-spectrum caspase inhibitors not only 
prevented apoptosis but also caused a  reduction [by 2 log(10)] in production of progeny 
infectious viruses compared with untreated controls. Thus, permissive replication of AMDV in 
vitro in Crandel Feline Kidney (CrFK) cells depends upon activation of caspase-3. Furthermore, 
active caspase was shown to be required to specifically cleave NS1 protein at two sites, aa227 
(INTD↓S) and aa285 (DQTD↓S), and the cleavage products were crucial for the replication of 
AMDV genome (16). Importantly, the NS1 products could be identified in AMDV-infected cells 
but were not present in infected cells pretreated with caspase inhibitors. When the two caspase 
cleavage sites were mutated (D to E) in an infectious clone, replication of the clones containing 
either of these mutations was reduced by 3-4 log(10)-fold compared with that of the wild-type 
clone, and the clone with both mutations was replication defective. Mechanistically, 
immunofluorescence staining demonstrated that the cleavage was required for nuclear 
localization of NS1.  
Our recent work further demonstrated the critical role of caspase activation during 
productive infection of AMDV. We proved that expression of the viral capsid proteins alone can 
activate caspases, including caspase-10 which may serve as an initiator (42). In vitro caspase 
cleavage assays showed that the effector caspase-7 specifically cleaved the capsid protein VP2 
after D420. AMDV mutants that are resistant to caspase-mediated capsid cleavage increased 
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virus production by approximately 3-5 folds in CrFK cells. Thus, caspase-mediated specific 
cleavage of capsid proteins might have a role in regulating persistent infection of AMDV in 
animals. Collectively, caspase activation plays multiple roles in infection of AMDV through both 
promoting replication of the viral genome and limiting capsid production.  
The S-phase of the cell cycle was shown to be required for the expression of AMDV NS1 
protein (155). Cells that progressed through S-phase showed a characteristic binary pattern of 
cell cycle disturbance caused by AMDV infection. While a small portion of NS1-expressing cells 
escaped the G2/M cell cycle arrest and progressed to the G0/G1 phase, the majority were 
arrested at a post-mitotic phase with DNA content higher than 4N. Intriguingly, active DNA 
synthesis was detected in cells arrested at the post-mitotic phase, which implies the potential 
role of post-mitotic phase arrest for AMDV genome replication. Nevertheless, the nature of the 
post mitotic DNA content in arrested cells, whether of host or viral origin, is not clear. Which viral 
components are responsible for the cell cycle arrest still remains to be determined. 
In conclusion, apoptosis, and in particular, activated caspases, regulates AMDV infection 
by specific cleavage of both NS1 and capsid proteins. Infected cells with apparent cell cycle 
arrest still support AMDV replication.   
 
Bocavirus 
The importance of bocavirus infection was raised with the emergence of human 
bocavirus (HBoV).  HBoV infection is thought to be associated with pneumonia, and possibly 
gastroenteritis, mainly in children (5, 8, 99). As the in vitro infection of HBoV is far from efficient 
(64), it is currently difficult to reproduce HBoV infection in routine laboratory settings. The 
genetic map of HBoV1 was recently described and confirmed to be very close to that of MVC 
(36, 64). Therefore, the study of bocavirus-induced CPE is basically carried out with the two 
other members of bocavirus, namely minute virus of canines (MVC) and bovine parvovirus (BPV) 
(37, 175). 
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  Significant CPE has been observed during in vitro infection of Walter Reed canine 
cell/3873D (WRD) cells by MVC (19, 204). We have established an MVC infectious clone that 
produces infectious virus efficiently (204). We took advantage of the MVC in vitro infection 
system as a model for the bocavirus genus and explored the molecular mechanism underlying 
the cell death induced during bocavirus infection (37). As shown in Chapter 3, we found that 
MVC infection triggered replication-dependent, mitochondrion-mediated apoptosis, which can 
be blocked by a pan-caspase inhibitor. Moreover, the level of cell death correlated closely with 
the level of MVC replication. Expression of viral proteins individually or in combination failed to 
induce cell death in transfected cells.  
Along with apoptosis, we also observed a progressive cell cycle arrest of infected WRD 
cells (37). At around 18 hrs after infection with MVC, NS1-expressing WRD cells showed a 
single widened cell cycle peak with a plateau at S-phase, which progressed into prolonged 
G2/M arrest. The DNA content of NS1-expressing WRD cells did increase to slightly higher than 
4N at G2/M arrest. We believe this finding was the result of the replicated viral genome, which 
was quantified to be approximately 1/8 the amount of the human genome during active 
replication at 48 hrs post-infection. UV-inactivated MVC also induced cell cycle arrest at the 
G2/M but not S-phase. The cell cycle was gradually resolved without inducing significant level of 
cell death. Moreover, when transfected with a panel of mutants of the MVC infectious clone, 
MVC viral protein expression did not induce either apoptosis or cell cycle arrest, while the 
genome alone induced G2/M arrest, even when half of the left terminal repeat structure was 
deleted. The S-phase plateau, which has not been seen in other members of Parvovirinae, 
appeared only when active MVC replication took place.  
In contrast, CPE induced during BPV infection was shown to be mediated by necrosis 
rather than apoptosis (1). With the use of embryonic bovine tracheal cells, BPV infection did not 
cause alterations in nuclear morphology, membrane changes, apoptotic body formation, 
membrane phosphatidylserine inversions, caspase activation or cellular DNA fragmentation. On 
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the other hand, at the end of the virus replication cycle, infected cells released viral 
hemagglutinin and infectious virus particles, as would be expected from cell membrane failure. 
Moreover, the infected cells released lactate dehydrogenase, a marker of necrosis, which 
directly correlated with virus production. Furthermore, assessment of mitochondrial 
dehydrogenase activity was consistent with cell death by necrosis.  
Collectively, bocavirus infection induces either apoptosis or necrosis depending on the 
type of virus. Cell cycle manipulation by bocavirus is unique in that the S-phase plateau in early 
infection progresses into G2/M arrest at a later stage.   
 
Dependovirus 
AAVs have not been associated with any disease in humans (13). In fact, recombinant 
AAV has been favorably emphasized as a vector for human gene therapy (197, 198).  A series 
of reports emerged recently that investigated the cell death induced by AAV infection as well as 
the underlying mechanism (68, 179, 211). Identification of the AAV-mediated killing of cells 
lacking p53 activity has opened up the exploration of the oncolytic potential of AAV (179). The 
p53-p21-phosphorylated retinoblastoma protein (pRb) pathway protects normal cells from AAV 
induced apoptosis (77). The lack of this pathway, due to loss or mutation of p53, p21 or pRb, 
sensitized cells, particularly tumor cells, to AAV infection-induced apoptosis. Moreover, DNA 
damage effector kinase Chk1 was also suggested to be the mediator of apoptotic cell death 
induced during AAV infection of p53-deficient cells (95). In addition, it was reported that the 
nonstructural protein Rep78 of AAV2, independent of p53, induced apoptosis with activation of a 
caspase cascade (189).   
While apoptotic cell death was attributed to the activation of the caspase cascade, 
emphasis was placed on mechanistically linking the DNA damage response induced during 
AAV infection to cell cycle regulation and p53-independent cell death. G2/M arrest was 
observed during AAV infection, but intriguingly not in ATM-/- cells (179). S-phase progression of 
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infected cells was inhibited by AAV Rep78 via hypophosphorylation of Rb (187). In addition, the 
AAV2 genome was shown to trigger DNA damage signaling that resembles the response to an 
aberrant cellular DNA replication fork (96). The formation of DNA damage response foci induced 
by the AAV genome strictly depended on ATR (ATM and Rad3-related protein), Chk1 and DNA 
topoisomerase 2-binding protein 1 but not ATM or NBS1 (96). The p5 promoter sequence of 
AAV2 was identified to be responsible for inducing the host DNA damage response, which leads 
to the G2/M arrest (73). Furthermore, in p53-deficient cells, UV-inactivated AAV2 triggered 
mitotic catastrophe associated with a dramatic Chk1-dependent overduplication of centrioles 
and the consequent formation of multiple spindle poles in mitosis (90). In p53-proficient cells, 
H2AX was indispensible for the formation and maintenance of DNA repair foci induced by 
stalled replication and p21-mediated cell cycle arrest (74). Moreover, the activation of H2AX 
was shown to be the result of ATR overactivation and diffusion but independent of ATM.   
 AAV preferentially induces apoptotic cell death in p53-deficient cells, which lack the 
ability to maintain prolonged G2/M arrest via Chk1 mediated mitotic catastrophe. In p53-
proficient cells, AAV infection induced a G2/M arrest that was maintained via the ATR-Chk1-
H2AX-p53-p21 pathway preventing significant cell death. During co-infection with adenovirus, 
however, replication of the AAV2 genome induced a DNA damage response through activation 
of the primary mediator DNA-PKCs (47, 191).  
       
Parvovirus 
Cell death induced by members in the genus Parvovirus is cell type dependent. In tissue 
samples of cats and dogs with panleukopenia and enteritis, respectively, apoptosis has been 
shown to contribute significantly to the widespread tissue damage caused by parvovirus 
infection (12). Apoptotic cell death induced by H-1 parvovirus (H-1PV) has been reported (153, 
181, 184); however, necrosis also has been shown to mediate the H-1PV-induced CPE in 
apoptosis-resistant cell types (63), and MVM-induced CPE in permissive murine A9 cells (149).   
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The oncolytic potential of rodent parvoviruses, particularly MVM and H-1PV, has drawn 
attention for decades. A rich body of studies has emphasized the CPE induced by MVM and H-
1PV, which is selectively seen in tumorized cells, but not their normal counterparts. The 
selective killing of tumorized cells by MVM and H-1PV was shown in vitro in cultured SV40-
transformed cells over 20 years ago (41, 137). A series of animal experiments showed the 
suppressive effect of MVM and H-1PV on different tumors or tumor grafts (102). Stimulation of 
the parvovirus life cycle, or lytic activation in tumorized cells vs. normal counterparts, was 
proposed as the mechanism behind the oncolytic function based on the observation that a 
higher level of viral replication and production was achieved in tumorized cells than in non-
transformed cells (49, 50). This hypothesis is sound given that S-phase, which is pivotal for 
parvovirus replication, is more active in tumorized cells. On the other hand, the NS1 protein 
expression level and phosphorylation status, which differs in tumorized cells vs. their normal 
counterparts, may also contribute to the selective killing function (54, 136, 146, 147).  
  The CPE induced by MVM infection, shown mainly to affect micro and intermediate 
filaments of the cytoskeleton network, while the nuclear lamina and microtubules remain intact 
throughout infection (148), is mainly caused by the activity of NS1 (48). The interaction of MVM 
NS1 and casein kinase II (CKII) was revealed to mediate CKII-dependent cytoskeletal 
alterations and non-apoptotic cell death in murine A9 fibroblasts (150). NS1 acted as an adaptor 
molecule, linking the cellular protein kinase CKIIα to tropomyosin and thus modulating the 
substrate specificity of the kinase. This action results in an altered tropomyosin phosphorylation 
pattern both in vitro and in living cells. Moreover, NS1 mutants that abolished binding with either 
CKIIα or tropomyosin lost the capacity of inducing CPE. The fusion peptide, in which the 
tropomyosin-binding domain of NS1 and CKIIα are physically linked, was able to mimic NS1 in 
its ability to induce death of transformed MVM-permissive cells. In addition, the Raf-1 signaling 
control of nuclear transport was suggested to be the target during MVM infection-induced 
oncolysis (182). 
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As for H-1PV, necrosis was detected in infected glioma cells which are resistant to 
cisplatin and TRAIL-induced apoptosis. H-1PV has been found to kill glioma cells via a non-
apoptotic cell death mechanism mediated by cathepsins (63). Lysosomal membrane 
permeabilization and the resulting release of lysosomal enzymes, and in particular cathepsins, 
into the cytosol is the main pathway to mediate this type of cell death (72, 82). In contrast, in a 
recent report, H-1PV NS1 was shown to induce apoptotic cell death via induction of reactive 
oxygen species in 293 cells, which is inconsistent with the observation in H-1PV infection of 
NB324K, an SV40-transformed human cell line (88). Inhibition of reactive oxygen species by a 
different reducing compound significantly decreased NS1-induced apoptosis. More importantly, 
H-1PV kills human hepatocellular carcinoma cell line (QGY-7703) cells by a non-apoptotic 
process, though a cDNA microarray analysis of H-1 PV-infected cells showed that genes 
involved in signal transduction, apoptosis, DNA replication, DNA repair, DNA binding and 
transcription were differentially expressed after H-1PV infection (112).   
 As seen in other genera, members of the genus Parvovirus are also able to induce cell 
cycle arrest during infection. An increased S/G2/M-phase population was observed during MVM 
infection (7, 156-158). G2/M arrest was also detected during H-1PV infection (88). MVM-
induced cell cycle arrest in S-phase was shown to be p53-dependent but p21cip1-independent, 
whereas the arrest in G2 was dependent on both p53 and its downstream effector p21cip1 (158). 
The MVM NS1 protein alone was able to reproduce cell cycle arrest as seen during MVM 
infection (7, 158). An early study implied one of the possible mechanisms underlying MVM NS1-
induced cell cycle arrest was the direct nicking of the host cell chromatin by NS1, which took 
place hours before the cell cycle arrest (157). The damaged chromatin DNA might induce a 
DNA damage response, which in turn stalls the cell cycle for repair. Indeed, a DNA damage 
response, together with cell cycle arrest and apoptosis, was detected during H-1PV infection 
(88), as well as during MVM infection (Pintel D, personal communication). However, whether the 
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viral genome or the nicked host chromatin triggered the DNA damage response remains 
unanswered.  
Taken together, the CPE induced by members in the genus Parvovirus could be either 
necrosis or apoptosis, depending on the virus and cell type. The NS1 protein clearly plays a role 
in inducing cell death and cell cycle arrest of infected cells via multiple strategies.  
 
Discussion 
 Parvoviruses induce both cell death and cell cycle arrest during infection. While 
necrosis was reported during BPV, MVM and H-1PV infection, apoptosis has been 
demonstrated as the major pathway mediating parvovirus infection-induced cell death. The cell 
cycle perturbation during parvovirus infection mainly appears as G2/M-phase arrest. However, 
S-phase plateau was also reported during MVC infection, through an accumulated/prolonged S-
phase (37).  
From an organismal standpoint, apoptosis induced during virus infection is thought to be 
a means for the host to defend itself against viral invasion (207). However, apoptosis may also 
represent a crucial step in the viral life cell cycle and pathogenesis (15, 145) as apoptotic cell 
death allows for viral release and induces less immune response than cell lysis, which releases 
cellular components and triggers an inflammation response (84). In some cases, caspase 
activation is clearly required to regulate DNA replication and virion production through caspase-
mediated specific cleavage of AMDV NS1 and VP2 (16, 17). Apoptotic cell death apparently is a 
direct cause of diseases during parvovirus infection, especially anemia and fetal death induced 
during B19V infection (6, 29), and possibly  gastroenteritis and pneumonia caused by parvovirus 
(167). The oncolytic effect of AAV relies on the selective induction of apoptosis in p53-deficient 
or tumorized cells (170). It may not be critical for the virus life cycle in natural infection with 
adenovirus (191); however, its potential implication is valuable. MVM and H-1PV can induce cell 
death in a number of tumor cells while having no cytotoxic effect on healthy tissues. The 
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mechanism underlying specific cell death of tumorized cells by these viruses is still unclear. H-
1PV infection can induce either necrosis or apoptosis, depending on the types of tumorized cells 
(129, 180, 181).   
Virus infection-induced cell cycle arrest has been extensively documented both in DNA 
and RNA viruses (56, 228).  The S-phase is generally critical for parvovirus replication, which 
takes place in the nucleus and utilizes host polymerase (66, 124, 183, 221). H-1PV protein 
synthesis coincides with the cellular DNA synthesis (210), while MVM replication has been 
shown to require mitotically active cells (81). B19V showed a maximal rate of transcription 
preceding the onset of S-phase dependent replication of the viral genome (24). The prevention 
of S-phase was reported to decrease the gene targeting of AAV2 (213). Though AAV2 infection 
has not been reported to elicit S-phase arrest (87, 96, 220), the AAV2 Rep78 was shown to 
inhibit Cdc25A and arrest the transfected cells at S-phase (14). Thus, it is reasonable to 
speculate that parvoviruses have the common feature of prolonging the S- or G2-phase in favor 
of their replication. The G2/M-phase arrest is more likely a pseudo-S-phase, with stalled host 
DNA replication but an active environment to facilitate viral DNA replication (56). The post-
mitotic arrest seen during AMDV infection indicates that the active DNA replication environment 
is maintained at cell cycle check point arrest (155). In concert, active BrdU incorporation was 
seen in parvovirus-infected cells with apparent G2/M-phase arrest (157, 187).  
Cell cycle disturbance and programmed cell death are two relatively separate events; 
however, increasing evidence suggests their crosstalk. Prolonged cell cycle arrest can induce 
apoptosis (122, 216) that is mediated through cyclin/cyclin dependent kinase and Bcl2 family 
proteins (231). A balance between cell cycle checkpoint maintenance and apoptosis is finely 
regulated during DNA damage to ensure the accuracy of replication and minimize the unwanted 
loss (46). The terminal repeat structures of parvoviruses can be easily detected as damaged 
DNA, thus triggering a DNA damage response, which in turn induces cell cycle arrest for “repair”. 
As replication of parvovirus requires cellular DNA polymerase (53), parvovirus replication favors 
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cells in S-phase in which active polymerase and other replication factors are present (143). It is 
logical to hypothesize that parvoviruses use parts of the single-stranded genome, especially the 
terminal repeats and/or the left hand promoter region, as triggers to induce a DNA damage 
response to prolong the S- and G2-phase during the early stage of infection, but not induce 
apoptosis. At this stage, active DNA polymerase and other necessary replication factors are 
present and used for genome replication. This hypothesis is supported by the fact that inhibition 
of DNA damage response significantly reduced AAV Rep expression (191), as well as MVC 
(Luo Y & Qiu J, unpublished) and MVM replication (Pintel D, personal communication). At the 
late stage of infection, the collaboration of “irreparable damage” and viral pro-apoptotic protein 
breaks the balance created by checkpoint arrest and leads to apoptosis, which is beneficial for 
viral egress. In addition, apoptosis is also likely contributed by a cellular mechanism to defend 
virus infection if the virus infection cannot be cleaned or limited in the cells.   
 
Concluding remarks:   
The CPE induced during parvovirus infection is mediated either by apoptosis or necrosis, 
and is contributed by cell cycle arrest, mostly at G2/M. While cell cycle arrest and caspase 
activation create an optimum environment for parvovirus replication at the early stage of 
infection, the ultimate induction of apoptosis is believed to be beneficial for virus egress at the 
late stage. The mechanism underlying induction of cell cycle arrest is likely due to a DNA 
damage response induced by the viral genome via the terminal repeats and left hand promoter 
region. Yet, apoptosis could be the ultimate consequence of the pro-apoptotic activity of viral 
proteins, prolonged cell cycle arrest and irreparable DNA damage response to ensure the 
optimum release of virion. Interestingly, parvovirus infection also uses a novel necrotic 
mechanism to induce cell death when apoptotic cell death cannot be achieved during virus 
infection, as seen in H-1PV infection, where the cell death mechanism of H-1PV varies 
depending on the host. Thus, parvovirus infection may provide a unique model to investigate the 
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virus-host interaction network that fine tunes the balance among DNA damage response, viral 
DNA replication, cell cycle arrest and cell death.    
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Part II. Human Parvovirus B19 
B19V was discovered by Australian scientist Yvonne Cossart in 1975 (51). It is a non-
enveloped, icosahedral virus with a size of about 20-25 nm. B19V has a linear single-stranded 
DNA (ssDNA) genome of 5.6 kb, with terminal repeats at both ends (Fig.1-1). Approximately 
equal numbers of positive and negative stranded DNA are packaged in separate virions.   
Replication of parvoviruses was only studied in AAV and MVM. A rolling hairpin 
replication model of the parvovirus genome has been confirmed in AAV and MVM DNA 
replication (53, 102 ) (Fig. 1-2). Briefly, the free 3’-OH group of the left terminal repeat serves as 
a primer, as a result of the hairpin structure, to produce a double-stranded monomer replication 
form (mRF). Viral NS1 protein then recognizes and specifically cleaves the mRF. The 3’-OH of 
the nicked site in turn primes the strand displacement DNA synthesis, yielding an intermediate 
with an open right-hand end. Via a process called “reinitiation”, the open end of the intermediate 
forms a double-hairpin conformation. Consequently, another round of strand displacement DNA 
synthesis takes place to produce the double replication form (dRF).  
Study of B19V replication has been limited by the lack of a highly permissive culture 
system and an infectious clone until recently (222, 230). The replication mechanism of the B19V 
genome is not yet understood, though a model of replication, which is similar to the “rolling-
hairpin” model, was proposed (Fig. 1-2) (53). The terminal hairpin structures of a single 
stranded B19V genome were observed under the electron microscope (10) and were confirmed 
by priming DNA synthesis using E. coli. DNA polymerase in vitro (52). Using blood samples 
from patients with acute B19V infection, three major replication forms of B19V, dRF, mRF and 
ssDNA genome, were shown (109). Depending on the sequence variation, the mRF sometimes 
was susceptible to BamHI digestion, producing two smaller fragments at 3.9k and 1.5k bps 
respectively. The infectious clone was then shown clearly to produce mRF at a size of ~ 5.6 k 
bps, which was digested by BamHI to two fragments, 4.1 and 1.5k bps respectively, in 
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transfection of UT7/Epo-S1 cells. We recently showed that in the presence of adenovirus or 
adenovirus gene products (E2a, E4orf6, and VA RNA genes), the B19V genome can replicate in 
293 cells, which are non-permissive to B19V infection, and produce infectious virus (80). Using 
this replication system, our lab identified the terminal resolution site and the NS1 binding site on 
the right terminal palindrome of the viral genome, which is composed of a minimal origin of 
replication spanning 67 nucleotides.  
A single pre-mRNA is transcribed from the single promoter at unit 6 during B19V 
infection. It is extensively processed by alternative splicing and alternative polyadenylation to 
generate a total of 12 transcripts (114). Blockade of the production of full-length B19V 
transcripts by the internal polyadenylation site [(pA)p] was previously reported to be a limiting 
step in B19V permissiveness (113). In the absence of genome replication, internal 
polyadenylation of B19V RNAs at (pA)p was favored in both permissive and nonpermissive cells. 
Recently, our lab demonstrated that replication of the B19V genome, however, enhanced read-
through of (pA)p and the polyadenylation of B19V transcripts at the distal site [(pA)d] (79). 
Therefore, replication of the B19V genome facilitates the generation of sufficient full-length 
transcripts that encode the viral capsid proteins and the essential 11kDa nonstructural protein. 
Furthermore, polyadenylation of B19V RNAs at (pA)p likely competes with splicing at the 
second intron (Guan W & Qiu J, unpublished). Thus, replication of the B19V genome is the 
critical limiting step governing B19V tropism in addition to virus entry. 
B19V shows exclusive tropism to erythroid progenitor cells during infection (163, 199). 
Both the more-primitive erythroid progenitors [burst-forming units-erythroid (BFU-E)] and the 
more-mature erythroid progenitors [colony-forming units-erythroid (CFU-E)] are susceptible to 
B19V infection (199). In addition to the primary erythroid progenitor cells, a few cell lines, 
basically myeloblastoid cell line like UT7/Epo-S1 (135) and KU812Ep6 (127), support B19V 
replication but at limited efficiency (3,45). Recently, ex vivo expanded CD36+ erythroid 
progenitor cells were reported highly permissive to B19V infection and support active B19V 
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replication (at least 100-fold increase of the B19V genome) (195, 222). The remarkable tropism 
of B19V to human erythroid progenitors was previously believed to be due to the receptor, 
blood-group P antigen (Globoside) (28), and co-receptors, namely KU80 and intergrin α5β1 
(127, 138).  
Erythropoiesis is the process whereby a fraction of primitive multipotent hematopoietic 
stem cells (CD34+) commit to the erythroid lineage, forming BFU-Es (early erythroid progenitors), 
CFU-Es (later erythroid progenitors), normoblasts, erythroblasts, reticulocytes, and ultimately 
the mature erythrocytes. While the early erythropoiesis is erythropoietin (Epo) independent (till 
BFU-E), the later stages are all Epo-dependent (from BFU-ECFU-E, which is highly Epo- 
responsive) (70).  
Erythropoietin (Epo) was shown to be required for susceptibility of human bone marrow 
cells to B19V infection (206). From this Epo depending, a conclusion was drawn that the target 
cells of B19V are in erythroid lineage from BFU-Es to erythroblasts, with permissiveness to 
B19V increasing along differentiation. Thus, the role of Epo for B19V infection was thought 
mainly to differentiate bone marrow hematopoietic stem cells (HSCs) to the stage of erythroid 
progenitors. However, it has been shown that Epo is also required for proliferation of  UT7/Epo-
S1 cells that are B19V semi-permissive cell line cells (135). Hence, the importance of Epo 
during B19V infection may not be solely for differentiation and maturation of erythroid 
progenitors. Nevertheless, the precise role of Epo during B19V infection is not clear.  
Epo elicits its function via ligation to its receptor EpoR (115). The Epo/EpoR complex 
formation induces autophosphorylation of Janus kinase 2 (Jak2), which further phosphorylates 
multiple tyrosine residues on the cytosolic domain of EpoR. The phosphorylation sites serve as 
docking sites for signaling molecules, e.g., signal transducer and activator of transcription 5A 
(STAT5A), Phosphoinositide 3-kinase (PI3K), growth factor receptor-bound protein 2 (Grb2), etc. 
Those signaling molecules further carry out the functions delegated from the Epo/EpoR ligation.  
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Based on the evidences listed above, we hypothesize that cellular microenvironment is 
the essential determinant of B19V permissiveness. It is realized only when the cellular 
environment permits replication of the viral genomes after their entry into cells. Not only is Epo 
crucial for cell proliferation and differentiation, but also its signaling is directly essential for tuning 
cellular microenvironment in favor of replication of the B19V genome. In Chapter 4, our studies 
demonstrate that Epo/EpoR/Jak2 signaling is indeed required for the replication of B19V 
genome so that confers B19V permissiveness in erythroid progenitor cells. The inhibition of 
Jak2 phosphorylation by a specific inhibitor or protein level by lentiviral shRNA significantly 
blocked B19V replication, whereas the cell cycle and viability of the treated cells were not 
significantly affected.  
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Fig. 1-1 Transcription map of B19V. The genome of B19V shown in this figure is based on the 
sequence of isolate J35 (GenBank accession no. AY386330), which is approximately 5.6 kb. 
The major transcription landmarks include the terminal repeats, P6 promoter, splice donors (D1 
and D2) and acceptors (A1-1, A1-2, A2-1, and A2-2) and the (pA)p and (pA)d sites.  All 12 
major transcripts are listed below the map (designed R1 through R9), with their sizes and 
encoded proteins shown to the right. RNA transcripts that are polyadenylated at the minor (pA)p 
site are designated as R1’, R2’ and R3’.   
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Fig. 1-2. Models of parvovirus DNA replication (80). (a) The 3’-OH group of the left hand 
terminal repeat serves as a primer to initiate the synthesis of viral genome forming a duplex 
DNA molecule that is covalently closed at one end by the hairpin structure. This procedure 
yields the mRF. (b) Viral NS1 protein (red filled circle) recognizes the target sequence on 
terminal repeat and specifically cleaves it. (c) The 3’-OH of the nicked site further primes the 
DNA synthesis to produce an intermediate with an open end at the right-hand side as shown in 
(d). (e) The newly synthesized strand is then denatured and reannealed, a.k.a. “reinitiation”, to 
form an intermediate with double-hairpin conformation. (f) Another round of strand displacement 
synthesis is initiated using the free 3’-OH of the double-hairpin conformation. This step finally 
yields the dRF. L, L-terminal repeat; R, R-terminal repeat.   
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Chapter 2 
The small 11kDa non-structural protein of human parvovirus B19 
plays a key role in inducing apoptosis during B19 virus infection of 
primary erythroid progenitor cells  
 
Abstract 
Human parvovirus B19 (B19V) infection shows a strong erythroid tropism and drastically 
destroys erythroid progenitor cells, thus leads to most of the disease outcomes associated with 
B19V infection. In this study, we systematically examined the three B19V nonstructural proteins, 
7.5kDa, 11kDa and NS1, for their function in inducing apoptosis in transfection of primary ex 
vivo expanded erythroid progenitor cells, in comparison with apoptosis induced during B19V 
infection. Our results show that 11kDa is a more significant inducer of apoptosis than NS1, while 
7.5kDa does not induce apoptosis. Furthermore, we determined that caspase-10, an initiator 
caspase in death receptor signaling, is the most active caspase in apoptotic erythroid 
progenitors induced by 11kDa and NS1 as well as during B19V infection. More importantly, 
cytoplasm-localized 11kDa is expressed at least 100 times more than nucleus-localized NS1 at 
the protein level in primary erythroid progenitor cells infected with B19V; and inhibition of 11kDa 
expression using anti-sense oligos targeting specifically to the 11kDa-encoding mRNAs reduce 
apoptosis significantly during B19V infection of erythroid progenitor cells. Taken together, our 
results demonstrate for the first time that 11kDa plays a key role in executing erythroid 
progenitor cell death during B19V infection.    
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Introduction 
 B19V infection is the cause of "fifth disease", a highly contagious infection of childhood. 
B19V infection can result in serious and occasionally fatal hematologic diseases in susceptible 
patients (227). In patients with increased destruction of red cells and a high demand for the 
production of erythrocytes, acute B19V infection can cause transient aplastic crisis. Pure red-
cell aplasia can also be a manifestation of persistent B19V infection in immunocompromised or 
immunodeficient patients.   
B19V belongs to the genus Erythrovirus in the family Parvoviridae (208). Spanned by 
two identical terminal hairpin repeats, the 5.6-kb linear single stranded DNA genome of B19V 
encodes a single nonstructural protein (NS1), and two capsid proteins (VP1 and VP2). Two 
other smaller non-structural proteins, 7.5kDa and 11kDa, have been detected during B19V 
infection (118, 200). The 11kDa protein is translated from a small left-ORF that overlaps with the 
C-terminal of the VP1/VP2 ORF in a different frame. The 7.5kDa protein is translated from a 
small mid-ORF. NS1 is a multiple functional polypeptide essential to viral replication and 
regulation of gene expression that is cytotoxic to host cells (27, 131, 161, 178). The 11kDa 
protein has been shown to have a role in virion production and trafficking in infected cells, while 
the 7.5kDa protein has not yet been reported to have functions during B19V infection (229).  
B19V shows extreme tropism for erythroid progenitor colony forming unit-erythroid cells 
(CFU-E) and burst-forming unit-erythroid cells (BFU-E) in the bone marrow of patients (162, 163, 
199). Disease manifestations of B19V infection, as seen in transient aplastic crisis, pure red cell 
aplasia and hydrops fetalis, are due to the direct cytotoxicity of the virus (29), a direct outcome 
of the cell death of erythroid progenitors that are targets of B19V replication. A progressive host 
cell apoptosis has been identified during B19V infection of primary erythroid progenitor cells and 
megakaryoblastoid cell lines (131, 195). NS1 expression in megakaryoblastoid cell lines has 
been associated with B19V-induced apoptosis (131, 195); however, the kinetics of NS1 
expression has not correlated with that of induced apoptosis during B19V infection of 
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megakaryoblastoid cell line UT7/Epo-S1, which are semi-permissive to B19V infection (45, 135). 
These findings raise the question about the role of NS1 in inducing apoptosis during B19V 
infection.  
In the present study, we show for the first time that 11kDa is a more significant inducer 
of apoptotic cell death than NS1 in transfection of primary erythroid progenitor cells. Since 
11kDa is expressed at least 100 times more than NS1 at the steady-state protein level  in 
erythroid progenitor cells during B19V infection, we conclude that the B19V infection-induced 
apoptosis of erythroid progenitor cells, is largely mediated by the small non-structural 11kDa 
protein.   
 
Materials and Methods 
Cells and virus infection:  
 HeLa cells, 293 cells, K562 cells and UT7/Epo-S1 cells were maintained as previously 
described (79, 176). Human primary CD36+ erythroid progenitor cells (CD36+ EPCs) were 
expanded ex vivo in the expansion medium as previously described (79, 222). Large numbers 
of CD36+ EPCs, which were used for either transfection or B19V infection, were obtained on day 
8 or day 9.  
Twenty microliters of B19V viremic plasma that contained 1 × 1012 copies of B19V 
genome per ml was incubated with 2 × 106 cells, in a volume of 500 µl medium with slow 
rotation at 4°C for 2 hrs. Infected cells were then cultured in the expansion medium at a 
concentration of 2 × 105 cells/ml at 37°C with 5% CO2.   
 
Caspase inhibitors:  
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Two general caspase inhibitors, pan-caspase fmk Inhibitor Z-VAD-fmk (Z-VAD) and Oph 
inhibitor Q-VD-Oph (Q-VD), and nine individual caspase inhibitors (caspase-1, -2, -3&7, -4, -6, -
8, -9, -10 & -13 inhibitors) were purchased from R&D Systems (Minneapolis, MN).   
 
Morpholino oligos: 
Three Morpholino anti-sense oligos were designed to specifically target sequences in 
the region of the AUG translation start site of the 11kDa-encoding mRNAs, which are diagramed 
in Fig. 2-5A. Their sequences written from 5’ to 3’ and complementary to the 11kDa-encoding 
mRNA are as follows: MO-1: TCTTCAGGCTTTTCATATCCATGTC; MO-2: 
CCATGTCTGTGGTGTTGTTTTGCAT and MO-3:  TGTAGAGTTCACGAAACTGGTCTGC. The 
Morpholino oligos were synthesized at Gene Tools, LLC (Philomath, OR), and Endo-Porter was 
used for delivery following a manufacturer protocol. A random control Morpholino was used as a 
control.   
 
Plasmid construction:  
NS1, 7.5kDa and 11kDa expression plasmids in mammalian cells: GFP was cloned 
into pNTAP-B (Strategene) by BamH I and EcoR I as pGFP. Then we cloned the NS1 ORF (nt 
616-2631), the 7.5kDa mid-ORF (nt 2090-2305) and the 11kDa ORF (nt 4890-5171) into this 
pGFP plasmid through EcoR I/Xho I sites as pGFP-NS1, pGFP-7.5kDa and pGFP-11kDa, 
respectively. pRFPHA, pRFP-NS1HA and pRFP-11kDaHA  were constructed by replacing GFP 
with RFPHA (C-terminal HA tagged red fluorescent protein, DsRed, Clontech), RFP-NS1HA and 
RFP-11kDaHA  (NS1 and 11kDa were HA tagged at C-terminal) in the pGFP, respectively.    
Bacterial expression plasmids of glutathione S-transferase (GST) fused B19V 
proteins:  The 11kDa ORF and the N-terminus encoding sequence (nts 616-1158) of the NS1 
were cloned into pGEX4T3 (GE Health) as pGEX11kDa and pGEXNS1(aa1-181), respectively.   
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All the nucleotide (nt) numbers refer to the sequence of the B19V J35 isolate (Genbank 
accession no.: AY386330). 
 
 Reverse transcription (RT)–real time PCR:  
A multiplex RT-real time PCR system was performed to detect B19V 11kDa-encoding 
and NS1-encoding mRNAs, with β-actin mRNA serving as an internal control as previously 
reported (80, 222).   
  
Production of antisera against B19V non-structural proteins:  
GST- fused full length 11kDa (GST-11kDa) and NS1 amino acids (aa) 1-181 [GST-
NS1(aa1-181)] were expressed and purified as we previously described (204). Polyclonal 
production was performed following protocols as previously described (204).   
 
Transfection: 
The 293 and Hela cells were transfected with 2 µg of DNA per 60-mm dish using 
Lipofectamine and Plus reagent (Invitrogen) as previously described (177). K562 cells were 
electroporated with 2 µg of DNA per 2 × 106 cells using reagent V and program T6 with the 
Amaxa® Nucleofector® (Lonza Inc.). UT7/Epo-S1 cells and CD36+ EPCs were electroporated 
with 2 µg of DNA per 2 × 106 cells, using a universal transfection reagent with program X-005 as 
previously described (79). After transfection, CD36+ EPCs were maintained in the expansion 
medium (79, 222).  
 
SDS-PAGE, Western blotting and immunofluorescence:  
SDS-PAGE, Western blotting and immunofluorescence assay were performed as 
previously described (174).   
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Flow cytometry analysis: 
AnnexinV/Propidium Iodide (PI) staining: Cells were stained alive with Cy5-
conjugated AnnexinV (BD Biosciences) and PI (Sigma) together to detect apoptotic cells 
according to the manufacturer’s instructions (BD Biosciences).   
TUNEL (Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling) assay: 
TUNEL assay was basically performed according to the manufacturer’s protocol (MBL 
International, MA) with the modification that streptavidin-Cy5 (Jackson ImmunoResearch, PA) 
was used to develop fluorescence.   
FLICA (Fluorochrome Inhibitor of Caspase Assay): Live cells (1 × 106) were stained 
with respective FAM-labeled FLICA peptide according to the manufacturer’s manual 
(Immunochemistry Tech, MN).   
All the samples were analyzed on the three-laser flow cytometer (LSR II, BD 
Biosciences) within an hour of staining at the Flow Cytometry Core on campus. All flow 
cytometry data were analyzed using FACS DIVA software (BD Biosciences). 
 
Results 
11kDa induces apoptosis in both B19V permissive and nonpermissive cells. 
To examine the potential role of 11kDa in inducing apoptosis, we transfected pGFP-
11kDa and pGFP plasmids, respectively, into both B19V permissive and nonpermissive cells. 
The GFP positive (GFP+) population was selectively gated and analyzed in comparison with the 
GFP negative [GFP(-)] population using AnnexinV/PI double staining. There were significantly 
more AnnexinV positive (AnnexinV+) cells in GFP-11kDa expressing UT7/Epo-S1, CD36+ EPCs, 
HeLa and K562 cells than these in GFP control expressing cells (Fig. 2-1 A&B, GFP+), but no 
significant difference was observed between the GFP-11kDa and GFP expressing 293 cells (Fig. 
2-2-1 A&B, GFP+ 293).  
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In UT7/Epo-S1 cells, the population of AnnexinV+ cells induced by GFP-11kDa reached 
a high rate of 48.0% at 48 hrs posttransfection in GFP+ cells (Fig. 2-2-1A, GFP+ S1). In contrast, 
GFP(-) cells in the same sample showed only 5.1% AnnexinV+ cells [Fig. 2-2-1A, GFP(-) S1]. 
Less than 13.1% of GFP+ cells in the pGFP-transfected cells (as control) were stained with 
AnnexinV (Fig. 2-2-1B, GFP+ S1). GFP-11kDa induced an average of 37.1% more AnnexinV+ 
cells in GFP+ cells than in GFP(-) cells at 48 hrs posttransfection (Fig. 2-2-1C, GFP-11kDa S1), 
indicating that the AnnexinV+ population of GFP+ cells in the pGFP-11kDa-transfected cells is 
predominately induced by the 11kDa, not the GFP. 
 The GFP-11kDa also induced a high AnnexinV+ population in CD36+ EPCs that are 
highly permissive to B19V infection in vitro and are the primary cells most closely resembling  
the CFU-E and BFU-E in the bone marrow of patients (222). Similar to UT7/Epo-S1 cells, GFP-
11kDa induced an average of 42.6% more AnnexinV+ cells in GFP+ cells than in GFP(-) cells at 
24 hrs posttransfection (Fig. 2-2-1C, GFP-11kDa CD36+). In comparison, pGFP control 
transfection only resulted in approximately 7% AnnexinV+ cells over the background (Fig. 2-2-
1C, GFP CD36+). Notably, we observed a significant amount of background cell death in 
transfected CD36+ EPCs, which presumably was induced by the electroporation and despite the 
optimized conditions that allowed us to transfect the CD36+ EPCs. At 24 hrs posttransfection, as 
much as 30% of the background AnnexinV+ population was detected in GFP(-) cells of pGFP-
transfected CD36+ EPCs [Fig. 2-2-1B, GFP(-) CD36+]. This amount increased to more than 50% 
at 48 hrs posttransfection, which made assessing apoptosis induced by transfection of the GFP-
11kDa less accurate (data not shown). Therefore, we chose to assay transfected CD36+ EPCs 
only at 24 hrs posttransfection.  
 The 11kDa also induced a significant amount of AnnexinV+ cells in B19V nonpermissive 
cells, HeLa and K562 cells, in addition to these B19V permissive cells. We observed more than 
30% of AnnexinV+ cells in GFP+ population of the pGFP-11kDa-transfected cells of both types 
at 48 hrs posttransfection (Fig. 2-2-1A, GFP+ HeLa&K562). Conversely, pGFP transfection  
34 
 
 
 
 
Fig. 2-1.  Transfection of 11kDa induces apoptosis in both B19V permissive and 
nonpermissive cells. (A&B) UT7/Epo-S1, CD36+ EPCs, HeLa, K562 and 293 cells were 
transfected with pGFP-11kDa plasmid (A) or pGFP as a control (B). CD36+ EPCs were stained 
at 24 hrs posttransfection; other cells were stained at 48 hrs posttransfection with AnnexinV/PI 
double staining, followed by flow cytometry analysis. Both GFP negative [GFP(-)] and positive 
(GFP+) cell populations were gated to plot cells by PI vs AnnexinV. Only a representative 
experiment is shown, and the percentage of each quadrant is indicated. AnnexinV+ population 
is a combination of the AnnexinV+/PI+ population (number in the upper right quadrant) with the 
AnnexinV+/PI(-) population (number in the lower right quadrant). (C) The experiments as 
described in A&B were performed at least three times independently. The percentage value of 
AnnexinV+/PI+ or Annexin V+/PI(-), as shown in individual panel with indicated cell type, was 
calculated by subtracting the AnnexinV+/PI+ population or the AnnexinV+/PI(-) population of 
GFP+ cells by that of GFP(-) cells (background apoptosis). (D) UT7/Epo-S1 cells were 
transfected with pGFP-11kDa and stained with DAPI. Confocal images were taken at a 
magnification of 60 × (objective lens) with an Eclipse C1 Plus confocal microscope (Nikon). 
Arrows show apoptotic nuclei, which were enclosed in the apoptotic bodies visualized by GFP 
fluorescence. S1: UT7/Epo-S1; CD36+: CD36+ EPCs; TX: transfection.  
Results that are shown as average ± standard deviation in all the figures are generated 
from at least three independent experiments. 
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alone only induced 10% and 8% of the AnnexinV+ population in GFP+ HeLa and K562 cells, 
respectively (Fig. 2-2-1B, GFP+ HeLa&K562). However, the GFP-11kDa was not able to induce 
a significant amount of AnnexinV+ population in 293 cells (Fig. 2-2-1 A&C, 293); E1b-19kDa 
protein that is expressed in 293 cells perhaps inhibits apoptosis in a way similar to that of Bcl-xL 
(123, 212). In the pGFP transfection control of all the five cell types, GFP did not significantly 
induce the AnnexinV+ population in GFP+ cells of transfected cells in comparison with that in 
GFP(-) cells (Fig. 2-2-1B). When we transfected the CD36+ EPCs, however, we noted a 
relatively high percentage of AnnexinV+ population in GFP(-) cells of both pGFP-11kDa- and 
pGFP-transfected cells (Fig. 2-2-1 A&B, CD36+), which indicated background cell death that 
was caused in part by the electroporation.    
The majority of AnnexinV+ cells induced by GFP-11kDa were PI stained negative 
[AnnexinV+/PI(-)], and thus were in the early or middle stage of apoptosis. Specifically, more 
than 80% of AnnexinV+ cells were PI stained negative in UT7/Epo-S1, HeLa and K562 cells, 
and 60% were PI stained negative in CD36+ EPCs [Fig. 2-2-1C, AnnexinV+/PI(-)]. The cell 
population of AnnexinV+/PI+ is an indicator of either late apoptosis or necrosis (Fig. 2-2-1C, 
AnnexinV+/PI+). In addition, we directly visualized a representative cell with GFP-11kDa 
expression with distinct cellular nucleus degradation. We also observed small apoptotic bodies 
enclosing a degraded nucleus by green fluorescence (Fig. 2-2-1D) (85, 232). Overall, these 
results suggest that the 11kDa induces cell death with apoptotic features rather than necrosis in 
both B19V permissive and nonpermissive transfected cells. Further supporting this finding, 
11kDa did not induce an AnnexinV+ cell population in 293 cells.    
  
11kDa is a more significant inducer of apoptosis than NS1.  
 The apoptotic nature of NS1 has not been examined in primary erythroid progenitor 
cells. We sought to determine which protein, 11kDa or NS1, was more potent in inducing 
apoptosis in UT7/Epo-S1 cells and CD36+ EPCs. For comparison, we also studied the 7.5kDa, 
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another small nonstructural protein shown to be expressed during B19V infection but with an 
unknown function (118).    
While the GFP-11kDa and the GFP-NS1 both extensively induced AnnexinV+ cells when 
transfected to UT7/Epo-S1 cells, the GFP-7.5kDa poorly induced the AnnexinV+ population in  
GFP+ cells (Fig. 2-2A). In a time-dependent manner, the GFP-11kDa caused the AnnexinV+ 
population to increase from less than 20% to more than 60%, at 24 to 72 hrs posttransfection 
(Fig. 2-2A). At all three time points, the extent of the GFP-11kDa-induced AnnexinV+ population 
was significantly higher than that induced by the GFP-NS1 (Fig. 2-2A). However, at 72 hrs 
posttransfection only, an increased population of AnnexinV+ cells, approximately 16%, was 
observed in pGFP-7.5kDa-transfected cells compared with the pGFP-transfected control (8%) 
(Fig. 2-2A). To better evaluate the potency of the NS1 and the 11kDa in inducing apoptosis, we 
normalized the level of AnnexinV+ population by the level of protein expression represented by 
the mean intensity of the green fluorescence of the GFP detected by flow cytometer (Fig. 2-2B) 
(94, 101, 201). Results normalized by GFP were plotted as relative values to that of the GFP+ 
population of pGFP-11kDa-transfected cells, which was arbitrarily set to 100% (Fig. 2-2C). 
Transfecting the GFP-11kDa induced approximately two-fold more AnnexinV+ cells than 
transfecting the GFP-NS1 did (Fig. 2-2C), indicating that the 11kDa is twice more potent in 
inducing apoptosis than the NS1 in UT7/Epo-S1 cells. However, the difference between the 
GFP control and GFP-7.5kDa transfection groups was not statistically significant after 
normalization, suggesting that the 7.5kDa is not a significant apoptosis inducer in UT7/Epo-S1 
cells.  
Similar results were obtained by transfecting CD36+ EPCs (Fig. 2-2D). At 24 hrs 
posttransfection, while pGFP control transfection induced approximately 10% AnnexinV+ cells 
in the GFP+ population of transfected cells, transfection of pGFP-7.5kDa, pGFP-NS1 and 
pGFP-11kDa induced a significantly higher level of the AnnexinV+ population, approximately 
22%, 36% and 42%, respectively (Fig. 2-2D). After normalized by the GFP expression level (Fig.  
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Fig. 2-2. Comparison of apoptosis induced by transfection of three B19V 
nonstructural proteins and by B19V infection. (A, B&C) Comparison of apoptosis induced 
by 7.5kDa, 11kDa and NS1 in UT7/Epo-S1 cells. UT7/Epo-S1cells were transfected with 
pGFP control, pGFP-7.5kDa, pGFP-11kDa and pGFP-NS1. Cells were analyzed at the three 
time points of posttransfection as indicated. (A) The absolute percentages of AnnexinV+ 
populations of GFP+ cells were subtracted by that of GFP(-) cells and are plotted to the time 
points of posttransfection as shown. (B) UT7/Epo-S1 cells were transfected with plasmids 
expressing GFP or GFP-fused proteins as indicated. The mean fluorescence intensity (MFI) of 
GFP or GFP-fused proteins was detected by flow cytometer and plotted at three time points 
posttransfection. (C) The absolute values shown in panel A were normalized by the MFI of GFP 
shown in panel B that serves as a marker of protein expression level. The normalized data were 
plotted as relative values to GFP-11kDa, arbitrarily set as 100%. (D, E&F) Comparison of 
apoptosis induced by 7.5kDa, 11kDa and NS1 in CD36+ EPCs. The same plasmids, as 
indicated, were transfected to CD36+ EPCs. (D) The absolute values of AnnexinV+ cells were 
plotted at 24 hrs posttransfection. (E) CD36+ EPCs were transfected with plasmids expressing 
GFP or GFP-fused proteins as indicated. The mean fluorescence intensity (MFI) of GFP or 
GFP-fused proteins was detected by flow cytometer and plotted at 24 hrs posttransfection. (F) 
Results shown in panel D were normalized by following the same method used in panel C. (G) 
Apoptosis induced during B19V infection of CD36+ EPCs. The extent of apoptosis induced 
by mock/B19V infection of CD36+ EPCs was detected by TUNEL assay. Cells were also 
immunostained at the time points as indicated with an anti-B19V capsid antibody (clone 521-5D, 
Millipore) at 1:100 dilution followed by a FITC-conjugated secondary antibody with the TUNEL 
assay simultaneously. Stained cells were analyzed by flow cytometer, and both capsid+ and 
capsid(-) cell populations of B19V infected cells were gated for TUNEL+ population.   
  The symbols of a single star and double stars indicate P<0.05 and P<0.01, respectively. 
S1: UT7/Epo-S1; CD36+: CD36+ EPCs; TX: transfection.  
39 
 
40 
 
2-2E), the GFP-11kDa induced approximately 1.5 times more AnnexinV+ cells than did the 
GFP-NS1 (Fig. 2-2F), results similar to those obtained with UT7/Epo-S1 cells (Fig. 2-2C). Again, 
the difference between the GFP-7.5kDa and GFP alone did not continue to be statistically 
significant after normalization (Fig. 2-2F). Given the unique nature of ex vivo culture of CD36+ 
EPCs (even the GFP control induced about 10% AnnexinV+ cells), we determined that the 
GFP-7.5kDa was not a significant inducer of apoptosis, and thus focused our study on the NS1 
and the 11kDa thereafter. 
For comparison, we also determined the apoptosis level represented by TUNEL positive 
(TUNEL+) population during B19V infection of CD36+ EPCs.  B19V infected positive (capsid+) 
population was specifically selected to assess the extent of nicked-DNA-containing cells, 
compared to those of the capsid negative [capsid(-)]  population. As shown in Fig. 2-2G, at 24, 
48 and 72 hrs pi, about 20%, 50% and 64% TUNEL+ populations were detected, respectively, 
in the capsid+ population. Interestingly, we also found a time-dependent increase of TUNEL+ 
population in the B19V uninfected infected [capsid(-)] cell population, from 2% at 24 hrs p.i. to 
19% at 48 hrs p.i., which rose to more than 25% at 72 hrs p.i. The TUNEL+ populations in 
capsid(-) cells is likely due to the sensitivity of the capsid-recognizing antibody, but not to the 
release of apoptosis-inducing molecules from infected cells (Fig. S4).  However, a significant 
difference was consistently found between the capsid+ and capsid(-) cell populations. Similar 
results were obtained when the NS1-expressed cell population was selected for TUNEL assay 
using the anti-NS1 sera (data not shown). Thus, our results confirmed the apoptotic nature of 
CD36+ EPCs during B19V infection.     
 
11kDa localizes dominantly in cytoplasm and is expressed at least 100 times more than 
NS1 during B19V infection of CD36+ EPCs.  
 Induction of apoptosis is often caused by accumulation of the apoptotic inducer in the 
cytoplasm, nuclear translocation is often a means to inactivate the apoptotic inducer (20, 169).  
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Fig. 2-3. Cellular localization and expression of 11kDa and NS1 in transfection.  
(A) Specificity of αNS1 and α11kDA polyclonal antibodies.  UT7/Epo-S1 cells transfected 
with pGFP-NS1 or pGFP-11kDa were stained with respective antisera followed by a Texas red- 
conjugated secondary antibody. Images were taken from an Eclipse SE TE2000-S UV 
microscope (Nikon) at a 20 × magnification. (B) Cellular localization of GFP-NS1 and GFP-
11kDa in transfected UT7/Epo-S1 cells and CD36+ EPCs. UT7/Epo-S1 cells and CD36+ 
EPCs were transfected with pGFP-NS1 or pGFP-11kDa and stained with DAPI at 48 hrs 
posttransfection. DAPI was used to stain the nuclei. The confocal images (both panel B and C) 
were taken at 60 × (objective lens) magnification with an Eclipse C1 Plus confocal microscope 
(Nikon). (C) Cellular localization of 11kDa and NS1 in B19V-infected CD36+ EPCs. Infected 
CD36+ EPCs (at 48 hrs p.i.) were stained with α11kDa and αNS1 antisera followed by a Texas 
red-conjugated secondary antibody, respectively. DAPI was used to stain the nuclei. (D) The 
protein levels of GFP-NS1 and GFP-11kDa in transfected UT7/Epo-S1 cells and CD36+ 
EPCs vs  the NS1 and the 11kDa expressed in B19V-infected CD36+ EPCs, respectively. 
UT7/Epo-S1 cells and CD36+ EPCs were transfected with either pGFP-11kDa or pGFP-NS1 
and stained at 48 hrs posttransfection. CD36+ EPCs were infected with B19V and stained at 48 
hrs p.i. Cells were fixed with 1% paraformaldehyde and permeabilized in 0.2% Tween-20. Either 
α11kDa or αNS1 antisera at a dilution of 1:100 was used to immunostain cells, followed by a 
Cy5-conjugated secondary antibody. Stained cells were analyzed by flow cytometer. The 
protein level, represented by the mean fluorescence intensity, was compared between 
transfected and infected cells. S1: UT7/Epo-S1; CD36+: CD36+ EPCs; TX: transfection.  
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By using anti-NS1 (αNS1) and anti-11kDa (α11kDa) specific sera (Fig. 2-3A), GFP-11kDa and 
GFP-NS1 in transfected UT7/Epo-S1 cells and CD36+ EPCs showed similar cellular localization 
as the 11kDa and the NS1 expressed in B19V-infected CD36+ EPCs (Fig. 2-3 B&C). The blue 
nuclear DPAI staining did not overlap with either the green GFP-11kDa (Fig. 2-3B) or the 11kDa 
stained with α11kDa (red) (Fig. 2-3C), indicating that the GFP-11kDa and the 11kDa localize 
predominantly in cytoplasm. Conversely, nuclear DAPI staining overlapped exactly with NS1 
stained with αNS1(red) in B19V-infected CD36+ EPCs (Fig. 2-3C), confirming that NS1 is 
expressed exclusively in nucleus in B19V infected cells as previously reported (172, 229). In 
pGFP-NS1-transfected UT7/Epo-S1 cells and CD36+ EPCs, the GFP signal diffused to 
cytoplasm to some extent, however, the GFP-NS1 localized mainly in the nucleus.    
We next compared the expression level of GFP-11kDa and GFP-NS1 with that of 11kDa 
and NS1, respectively, during B19V infection. The level of the GFP-11kDa in transfected 
UT7/Epo-S1 cells and CD36+ EPCs at 48 hrs posttransfection, as quantified by flow cytometry 
analysis using α11kDa antiserum, was approximately 12 times lower than that of the 11kDa 
expressed in B19V-infected CD36+ EPCs at 48 hrs p.i. (Fig. 2-3D, α11kDa), implying that a 
stronger proapoptotic effect is induced by 11kDa in B19V-infected CD36+ EPCs than that 
induced by the GFP-11kDa in transfected cells. In contrast, nearly twice as much GFP-NS1 was 
expressed in both transfected UT7/Epo-S1 cells and CD36+ EPCs cells at 48 hrs 
posttransfection than the NS1 expressed in B19V-infected CD36+ EPCs at 48 hrs p.i. (Fig. 2-3D, 
αNS1), indicating that the GFP-NS1 in transfected cells likely mimics the function of the NS1 
during B19V infection.   
 To determine the relative expression level of 11kDa and NS1 during B19V infection of 
the native targets, erythroid progenitor cells, we quantified the mRNA levels of the two non-
structural proteins using RT-real time PCR. By normalizing to copy numbers of β-actin mRNA 
(relative copies per β-actin mRNA), the 11kDa-encoding mRNA remained at a consistent level  
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Fig. 2-4. Quantification of 11kDa and NS1 expression during B19V infection of CD36+ 
EPCs.   
(A) Quantification of B19V 11kDa- and NS1-encoding mRNAs. CD36+ EPCs were infected 
with B19V. At 24, 48 and 72 hrs p.i., total RNA was isolated, treated with DNase, reverse-
transcribed and quantified for absolute copies of mRNA by multiplex real-time PCR for NS1-
mRNA/β-actin-mRNA and 11kDa-mRNA/β-actin-mRNA as described in Materials and Methods. 
The copy numbers of the 11kDa- and NS1-encoding mRNAs were normalized by copy numbers 
of β-actin mRNA in the same reaction and presented as numbers per copy of β-actin mRNA. 
 (B) Purity of purified fusion proteins GST-NS1(aa1-181) and GST-11kDa. Purified GST-
NS1(aa1-181) and GST-11kDa proteins were resolved in SDS-10%PAGE gel and stained with 
Coomassie blue as shown. (C&D) Quantification of the stead-state protein level of 11kDa 
vs NS1 during B19V infection. 100 ng of GST-NS1(aa1-181) and 100 ng of GST- 11kDa as 
seen in panel B and a serial dilution of them as shown were loaded in SDS-8%PAGE and SDS-
15%PAGE for Western blot (panel C&D, respectively). At 48 hrs p.i., 1.5 × 105  of CD36+ EPCs 
with or without (Mock) B19V infection were harvested, directly dissolved in SDS lysis buffer and 
loaded in lanes 6&7 (SDS-8%PAGE) and lanes 8&9 (SDS-6%PAGE) (panel C), and lanes 3&4 
(SDS-15%PAGE) (panel D). Results from lanes as indicated also were quantified with Quantity 
One software (GE Health) and plotted to the right in panel C&D. Arrow and arrow head in panel 
C show NS1 specific band and GST-NS1(aa1-181), respectively; and arrow and arrow head in 
panel D show 11kDa specific band and GST-11kDa, respectively. CD36+: CD36+ EPCs.   
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that was approximately 100 to 200 times higher than that of the NS1-encoding mRNA during the 
course of B19V infection (Fig. 2-4A).   
 Further, to ascertain the steady-state protein level of 11kDa and NS1 during B19V 
infection, we attempted to estimate the relative protein level of 11kDa vs. NS1 during B19V 
infection. GST-NS1(aa1-181) and GST-11kDa were purified (Fig. 2-4B). The purified protein 
standards (Fig, 4C, lanes 1-5 and Fig. 2-4D, lanes 1&2, respectively) and cell lysates from 
B19V-infected CD36+ EPCs (at 48 hrs p.i.) and mock cells were blotted with α11kDa and αNS1 
antisera, respectively (Fig. 2-4 C&D). We observed significant nonspecific protein bands by the 
αNS1 antisera; however, the blots clearly showed the specific NS1 band with both 8% and 6% 
PAGE gels (Fig. 2-4C, compare lane 6 with 7 and lane 8 with 9, respectively). The intensity of 
this specific NS1 band from B19V-infected CD36+ EPCs (Fig. 2-4C, lane 6) fell between 1.0 ng 
and 0.33 ng of the GST-NS1(aa1-181) standards (Fig. 2-4C, lanes 4&5). In contrast, the signal 
of the 11kDa from B19V-infected CD36+ EPCs was stronger than that from 100 ng of the GST-
11kDa (Fig. 2-4D, compare lane 3 with 1). This result suggests that during B19V infection of 
CD36+ EPCs at 48 hrs p.i., at a steady-state protein level, 11kDa expresses at least 100 times 
more than NS1 (Fig. 2-4 C&D), which presented during the course of B19V infection of CD36+ 
EPCs (Fig. S2).    
Both high expression and cytoplasmic localization of 11kDa and the low expression and 
nuclear localization of NS1 during B19V infection of CD36+ EPCs suggest the important role of 
the 11kDa in apoptosis of B19V-infected erythroid progenitors.       
 
 Inhibition of 11kDa expression by 11kDa-specific Morpholinos reduces apoptosis 
significantly during B19V infection of CD36+ EPCs. 
To confirm a key role of 11kDa in inducing apoptosis during B19V infection, we next 
applied specific Morpholino anti-sense oligos to knock down 11kDa expression through 
inhibition of translation initiation(32, 203). CD36+ EPCs were pre-treated with Morpholino oligos  
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Fig. 2-5. The inhibitory effects of 11kDa-specific Morpholinos on B19V-infection-
induced apoptosis. CD36+ EPCs were pre-treated with a control Morpholino (MO-Ctrl) or 
11kDa-specific Morpholinos, MO-1, MO-2 and MO-3, as indicated, at a final concentration of 6 
µM, 24 hrs prior to B19V infection. (A) A schematic diagram of the 11kDa-encdoing mRNA and 
targets for specific Morpholino is shown. Regions in the 11kDa-encoding mRNA that 
Morpholinos target are shown with their respective nucleotide numbers.  (B) Detection of B19V 
11kDa protein. The same samples used for TUNEL assay were used for Western-blot using 
anti-11kDa antiserum. Detection of β-actin using a polyclonal antibody (ab1801, Abcam) served 
as a loading control. (C) TUNEL assay was performed with co-staining of B19V capsid using an 
anti-B19V capsid antibody (clone 521-5D, Millipore) for selection of infected cells at 48 hrs p.i. 
by flow cytometer. The TUNEL+ population is shown as a percentage in capsid positive cells.   
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24 hrs prior to infection. The expression of 11kDa was reduced by approximately 60% in B19V-
infected CD36+ EPCs treated with MO-1, MO-2 and MO-3 at 48 hrs p.i., as indicated by 
Western-blot (Fig. 2-5B). Consequently, as a result, the level of apoptosis, indicated by TUNEL+ 
population, was reduced by approximately 20%, in comparison with the cells treated with the 
control Morpholino (MO-Ctrl) (Fig. 2-5C). The expression levels of NS1 and capsid protein VP1 
and VP2 were not affected with treatment of Morpholinos as determined (data not shown), 
indicating MO-1, MO-2 and MO-3 target specifically to the 11kDa-encoding mRNAs. Thus, we 
have demonstrated that inhibition of 11kDa expression reduces apoptosis during B19V infection 
of CD36+ EPCs, supporting a key role of the 11kDa in inducing apoptosis in B19V infection. 
        
Caspase-10 inhibitor is as effectively as pan-caspase inhibitors in reducing B19V- 
induced apoptosis. 
Transfecting UT7/Epo-S1 cells with GFP-11kDa, we observed an 80% inhibition of 
AnnexinV+ population at 48 hrs posttransfection when Q-VD, a newly developed pan-caspase 
inhibitor without cross-inhibition of cathepsin (34) was used at 10 µM (Fig. 2-6A). Among 
individual caspase inhibitors (caspase-1, -2, -3&7, -4, -6, -8, -9, -10 and -13 inhibitors), the 
caspase-10 inhibitor was particularly effective; treatment with caspase-10 inhibitor at 20 µM 
reduced the percentage of the AnnexinV+ population by 55%. However, treatments with 
caspase-1, -2, -3&7, -4, -6 and -8 inhibitors at 20 µM only reduced the AnnexinV+ population by 
approximately 20% at 20 µM. The inhibition of the GFP-NS1-induced AnnexinV+ population in 
UT7/Epo-S1 cells generally shared the same profile but had less sensitivity compared with the 
population induced by 11kDa. At 48 hrs posttransfection, less inhibition was observed in pGFP-
NS1-transfected cells with the treatment of the same dose of inhibitors; treatments with Q-VD, 
Z-VAD and caspase-10 inhibitor reduced the AnnexinV+ population by 55%, 45% and 40%, 
respectively (Fig. 2-6A). Notably, after transfecting both UT7/Epo-S1 cells and CD36+ EPCs, the 
percentage of the GFP+ population (out of the total) in pGFP-NS1-transfected cells was  
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Fig. 2-6. The inhibitory effects of caspase inhibitors on 11kDa/NS1- transfection-  
and B19V-infection-induced apoptosis. (A&B) Inhibitory effects of caspase inhibitors on 
apoptosis induced by 11kDa- and NS1-transfection. (A) UT7/Epo-S1 cells were transfected 
with pGFP-11kDa or pGFP-NS1. (B) CD36+EPCs were transfected with pGFP-11kDa and 
pGFP-NS1, respectively, as shown. Individual caspase inhibitors (at 20 μM), caspase-1, -2, -
3&7, -4, -6, -8, -9, -10, and -13 inhibitors, as indicated by 1, 2, 3&7, 4, 6, 8, 9, 10 and 13, and 
pan-caspase inhibitors, Z-VAD (20 μM) and Q-VD (10 μM) were applied at the time of 
transfection. DMSO served as a control at 0.5% v/v. Apoptosis was measured by AnnexinV/PI 
staining at different times posttransfection as indicated. The AnnexinV+/PI+ population is shown 
as a relative percentage (%) to the DMSO control that is arbitrarily set as 100%. (C) Inhibitory 
effects of caspase inhibitors on apoptosis induced by B19V infection. CD36+ EPCs were 
infected with B19V. Caspase inhibitors were applied upon infection at the concentrations 
described above. TUNEL assay was used to measure apoptosis induced in capsid+ cell 
population at 48 hrs p.i. by flow cytometer. The TUNEL+ population is shown as a relative % to 
the DMSO control, arbitrarily set as 100%. 
All the numbers shown as percentage (%) are averages from at least two individual 
experiments. 
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approximately 1.6 times that of pGFP-11kDa-transfected cells as determined by flow cytometer 
(data no shown). This perhaps can partially explain why pGFP-NS1-transfected cells were less 
sensitive to these caspase inhibitors. Nevertheless, caspase-10 inhibitor clearly was the most 
effective in inhibiting both GFP-11kDa- and GFP-NS1-induced apoptosis in transfected 
UT7/Epo-S1 cells. 
 As expected, a similar inhibitory effect of all the caspase inhibitors was observed after 
transfecting GFP-11kDa and GFP-NS1 in CD36+ EPCs (Fig. 2-6B). Q-VD treatment showed the 
strongest inhibition in both the GFP-11kDa- and the GFP-NS1-induced AnnexinV+ cells, 
followed by Z-VAD and caspase-10 inhibitor. Similar to UT7/Epo-S1 cells, the GFP-NS1-
induced AnnexinV+ cells were less sensitive to inhibition caused by caspase inhibitors. For 
example, caspase-10 inhibitor reduced the GFP-11kDa-induced AnnexinV+ population by 62%; 
however, the NS1-induced AnnexinV+ population was only inhibited by 45%.      
In B19V infection of CD36+ EPCs, Q-VD was also the most effective inhibitor in 
decreasing the TUNEL+ population (Fig. 2-6C). Treatment with QVD at 10 µM inhibited B19V 
infection-induced TUNEL+ population by an efficiency of 70%. Similar to what was observed in 
the above transfection experiments, treatment with caspase-10 inhibitor showed a particularly 
high potency in inhibiting TUNEL+ population induced by B19V infection compared to 
treatments with other individual caspase inhibitors. At 20 µM, both caspase-10 inhibitor and Z-
VAD treatments inhibited B19V infection-induced TUNEL+ population by more than 60%.          
Collectively, our results show that caspase-10 inhibitor is the most effective inhibitor 
besides the two pan-caspase inhibitors in GFP-11kDa and GFP-NS1 transfection-induced 
apoptosis as well as in B19V infection-induced apoptosis.  
  
Caspase-10 is the most active caspase in 11kDa/NS1 transfection- and B19V infection-
induced apoptosis.    
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 The proteolytic cleavage of poly(ADP-ribose)polymerase-1 (PARP1) is one of the 
hallmarks of apoptosis (100, 110). The cleaved PARP1 band at a size of approximately 85 kDa 
was specifically detected in pGFP-NS1- and pGFP-11kDa-transfected UT7/Epo-S1 cells (Fig. 2-
7A, lanes 5&6) as well as in B19V-infected CD36+ EPCs (Fig. 2-7A, lane 2), but not in GFP only 
transfected cells and mock cells (Fig. 2-4A, lanes 1, 3&4), supporting the apoptotic nature of cell 
death induced by transfection of the GFP-11kDa and the GFP-NS1 and by B19V infection. 
Moreover, the cleaved band of caspase-10 was specifically detected in the pGFP-NS1- and the 
pGFP-11kDa-transfected UT7/Epo-S1 cells (Fig. 2-7B, lanes 5&6, respectively), as well as in 
B19V-infected CD36+ EPCs (Fig. 2-7B, lane 2), but not in pGFP-transfected control cells (Fig. 2-
7B, lane 4) and mock cells (Fig. 2-7B, lanes 1&3), suggesting that the caspase-10 is activated in 
11kDa/NS1 transfection- and B19V infection-induced apoptosis. 
Since caspase-3&7, -6 and -8 were reported active in NS1-expressing cell lines and 
B19V-infected erythroid progenitor cells (131, 195), FLICA was employed to further evaluate the 
importance of the active caspase-10. Since GFP and FAM share similar excitation and emission 
wavelength, we transfected cells with RFP-11kDaHA, RFP-NS1HA and RFPHA (as a control). 
Cellular localization and expression level of these RFP fusion proteins were observed to be 
similar to that of GFP fusion proteins (data not shown). At 48 hrs posttransfection, RFP-NS1HA 
and RFP-11kDaHA activated caspase-10 in 24% and 48% of the transfected cells (αHA positive, 
HA+), respectively; in contrast, only 10% of RFPHA-expressing cells contained active caspase-
10 (Fig. 2-7C). Similarly, activation of caspase-10 was detected in more than 53% of B19V 
infected-CD36+ EPCs (capsid+) at 48 hrs p.i. (Fig. 2-7D). Not surprisingly, all other analyzed 
caspases (caspase-3&7, -6, -8 and -9) were also activated, however, at a much lower level, 
compared with capsaspe-10 in the RFP-NS1HA- and the RFP-11kDaHA-expressing cells (Fig. 
2-7C) and in CD36+ EPCs infected with B19V (Fig. 2-7D). Our results show that caspase-10 is 
the most active caspase both in 11kDa- and NS1-expressing UT7/Epo-S1 cells and in B19V-
infected CD36+ EPCs, and 11kDa is more efficient in activating caspase-10 than NS1.  
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 Fig. 2-7. PARP1 is cleaved and caspase-10 is the most active caspase in 11kDa/NS1- 
transfection- and B19V-infection-induced apoptosis. (A&B) Detection of cleaved PARP1 
and cleaved caspase-10. CD36+ EPCs were infected with B19V, and capsid+ cells were sorted 
at 48 hrs p.i. by flow cytometer. UT7/Epo-S1 cells were transfected with pGFP control, pGFP-
11kDa and pGFP-NS1. At 48 hrs posttransfection, the GFP+ populations of transfected cells 
were sorted by flow cytometer. (A) Sorted cells were used for detecting the cleaved PARP1 by 
Western blot using anti-cleaved PARP1 at a dilution of 1:1000 (Cell Signaling). (B) Sorted cells 
were used for detecting of active caspase-10 by Western blot using anti-caspase-10 at a dilution 
of 1:1000 (Sigma). Uninfected or pGFP transfected cells served as Mock as shown. The blots 
were reprobed with anti-β-actin (Sigma). (C) Detection of activated caspase-3&7, -6, -8, -9 
and -10 in 11kDa- and NS1- transfected cells. UT7/Epo-S1 cells were transfected with 
pRFPHA control, pRFP-11kDaHA and pRFP-NS1HA. FAM- labeled FLICA peptides, FAM-
DEVD-FMK, FAM-VEID-FMK, FAM-LETD-FMK, FAM-LEHD-FMK and FAM-AEVD-FMK, were 
used to detect active caspase-3/7, caspase-6, caspase-8, caspase-9 and caspase-10, 
respectively. Individual FLICA staining was performed to determine active caspases at 48 hrs 
posttransfection. Transfected cells were selected by intracellular staining of anti-HA tag at 1:100 
dilution (clone HA-7, Sigma), shown as HA+ and HA(-) respectively, and were plotted to FLICA 
signal detected by flow cytometer. (D) Detection of activated caspase-3&7, -6, -8, -9 and -10 
in B19V-infected CD36+ EPCs. CD36+ EPCs were infected with B19V. At 48 hrs p.i., cells were 
used for individual FLICA staining followed by intracellular staining with the antibody against 
B19V capsid. Both capsid positive and negative cells were plotted to FLICA signal detected by 
flow cytometer. TX: transfection.    
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Discussion 
 We report here for the first time that B19V 11kDa is a more significant inducer of 
apoptosis than NS1 during B19V infection of primary erythroid progenitor cells. B19V-11kDa–
induced apoptosis is mediated by caspase-10 as an initiator. Strikingly, 11kDa expresses at 
least 100 times more than NS1 at the protein level during B19V infection of primary erythroid 
progenitor cells. In contrast with NS1, which localizes exclusively in the nucleus, 11kDa 
localizes predominately in cytoplasm, where apoptotic inducers usually reside. Although we 
used GFP-fused 11kDa and NS1 to analyze apoptosis induced in transfected cells, localization 
of the fused proteins recapitulates their native cellular localization. Moreover, the protein level of 
11kDa in transfected cells was approximately 12 times lower than that during B19V infection of 
erythroid progenitor cells, while the level of the NS1 was comparable between transfection and 
infection. Therefore, the 11kDa-induced apoptosis by transfection closely reproduces apoptosis 
induced during B19V infection of primary erythroid progenitor cells. In addition, our results have 
shown that inhibition of 11kDa expression reduces apoptosis during B19V infection of CD36+ 
EPCs, and thus we conclude that the B19V 11kDa is the major functional protein in destroying 
erythroid progenitors during B19V infection.   
Apoptosis is defined mechanistically as regulated cell death involving the sequential 
activation of caspases. Activation of caspase-8, -9 and -10, which are believed to be the initiator 
caspases at the top of the caspase signaling cascade, leads to the activation of downstream 
caspases, including caspase-3,-6 and -7, which in turn induce apoptosis (40). As has been 
previously reported, caspase-3&7, -6 and -8 inhibitors can significantly reduce apoptosis 
induced by NS1 in established NS1-expressing cell lines (131, 195) as well as by B19V infection 
of erythroid progenitor cells (195), though at a high concentration of 200 µM. At this high 
concentration, we did observe more than 90% inhibition of cell death in both the transfection 
and infection system (data not shown). Instead of using such this “saturated” concentration, 
however, we applied the inhibitors at a low concentration (20 µM) to probe precisely the potency 
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of the individual caspase inhibitor. Using FLICA, we detected a significantly higher level of the 
active caspase-10 than caspase-3&7, -6, -8 and -9 in 11kDa/NS1-transfection- and B19V-
infection-induced apoptotic cells, strongly indicating that caspase-10 is the initiator caspase.  
Caspase-10, previously considered as the ortholog of caspase-8 (22), has been shown 
to be able to substitute the function of caspase-8 (104, 217). However, we found caspase-8 
could not be substituted for caspase-10 in our study, as caspase-8 inhibitor was not nearly as 
effective as caspase-10 inhibitor in counteracting apoptosis induced by 11kDa and NS1 
transfection in UT7/Epo-S1 and primary erythroid progenitor cells or induced during B19V 
infection of primary erythroid progenitor cells. In addition, the activation of caspase-10 is 
significantly higher than caspase-8 in both 11kDa- and NS1-transfected UT7/Epo-S1 cells and 
B19V-infected primary erythroid progenitor cells. This finding suggests a potential role of 
caspase-10 in the pro-apoptotic pathway that is not directly regulated by caspase-8.  
Notably, B19V permissive cells are erythroid or magakaryoblastoid cells that require Epo 
to sustain differentiation and proliferation. Epo positively regulates erythropoiesis by preventing 
apoptosis and stimulating differentiation and proliferation of erythroid progenitors and 
erythroblasts (107). We observed that the amount of Epo, ranged from 0.1 to 10 units/ml in 
B19V infection of erythroid progenitor cells, does not influence the degree of apoptosis 
significantly (Fig. S1). On other hand, the Fas/Fas ligand pathway has been identified to have 
an apoptotic role in the regulation of erythropoiesis (58, 59). Thus, the balance between the 
apoptosis by the Fas/Fas ligand and the antiapoptotic role in the presence of Epo is important 
for the homeostasis of erythroid progenitors.  Since Epo strongly presents an antiapoptotic 
stimulation, apoptosis induced during B19V infection may require a high level of a potent 
inducer that is the 11kDa.  We hypothesize that the high level of the 11kDa expression during 
B19V infection disturbs the balance between the apoptosis by the Fas/Fas ligand and the 
antiapoptotic role by Epo and further the homeostasis of erythroid progenitors. Thus, the B19V-
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11kDa-induced apoptosis provides us with a unique model to investigate further the mechanism 
underlying the caspase-10-dependent apoptosis, especially, in primary erythroid progenitor cells  
    Although an infectious clone of B19V was established, progeny virus produced from 
transfection of this clone is apparently limited, and transfection of an 11kDa-knockout-clone only 
results in a few assembled particles exclusively localized in the nucleus (229, 230). Therefore, 
we are unable to produce 11kDa-knockout virus to examine the role of the 11kDa in causing cell 
death of erythroid progenitors.  
Direct cell death of infected erythroid progenitors results in the disease outcome of B19V 
infection (29). B19V must express abundant executors to erythroid progenitors during infection, 
among which the 11kDa is the most significant and abundant executor. Collectively, our data 
demonstrate that the B19V 11kDa protein is the major protein in executing erythroid progenitor 
cell death during B19V infection by inducing apoptotic cell death during B19V infection of 
erythroid progenitor cells that is mediated by activating caspase-10.  
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Chapter 3 
Bocavirus infection induces a mitochondrion-mediated apoptosis and 
cell cycle arrest at G2/M-phase  
 
Abstract 
Bocavirus is a newly classified genus of the family Parvovirinae. Bocavirus minute virus 
of canines (MVC) infection produces a strong cytopathic effect in permissive Walter 
Reed/3873D (WRD) canine cells. We have systematically characterized the MVC infection-
produced cytopathic effect in WRD cells, namely, the cell death and cell cycle arrest, and 
carefully examined how MVC infection induces the cytopathic effect. We found that MVC 
infection induces an apoptotic cell death characterized by Bax translocalization to the 
mitochondrial outer membrane, disruption of the mitochondrial outer membrane potential, and 
caspase activation. Moreover, we observed that the activation of caspases occurred only when 
the MVC genome was replicating, suggesting that replication of the MVC genome induces 
apoptosis. MVC infection also induced a gradual cell cycle arrest from the S-phase in early 
infection to the G2/M-phase at a later stage, which was confirmed by the upregulation of cyclin 
B1 and phosphorylation of cdc2. Cell cycle arrest at the G2/M-phase was reproduced by 
transfection of a non-replicative NS1 knock-out mutant of the MVC infectious clone, as well as 
by inoculation of UV-irradiated MVC. In contrast with other parvoviruses, only expression of the 
MVC proteins by transfection did not induce apoptosis or cell cycle arrest. Taken together, our 
results demonstrate that MVC infection induces a mitochondrion-mediated apoptosis that is 
dependent on the replication of the viral genome, and the MVC genome per se is able to arrest 
the cell cycle at the G2/M-phase. Our results may shed light on the molecular pathogenesis of 
Bocavirus infection in general.    
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Introduction 
The Bocavirus genus is newly classified within the subfamily Parvovirinae of the family 
Parvoviridae (38). The currently known members of the Bocavirus genus include bovine 
parvovirus type 1 (BPV1) (39), minute virus of canines (MVC) (190), and the recently identified 
human bocaviruses (HBoV, HBoV2 and HBoV3) (5, 8, 99).   
MVC was first recovered from canine fecal samples in 1970 (18). The virus causes 
respiratory disease with breathing difficulty (33, 91, 173) and enteritis with severe diarrhea (19, 
128), which often occurs with co-infection of other viruses (128), spontaneous abortion of 
fetuses and death of newborn puppies (33, 86). Pathological lesions in fetuses in experimental 
infections were found in the lymphoid tissue of the lung and small intestine (33). MVC was 
isolated and grown in the Walter Reed/3873D (WRD) canine cell line (18), which is derived from 
a subdermoid cyst of an irradiated male dog (18). The full length 5.4-kb genome of MVC was 
recently mapped with palindromic termini (209). Under the control of a single P6 promoter, 
through the mechanism of alternative splicing and alternative polyadenylation, MVC expresses 
two nonstructural proteins (NS1 and NP1) and two capsid proteins (VP1 and VP2). Like the NS1 
proteins of other parvoviruses, the NS1 of MVC is indispensible for genome replication. The 
NP1 protein, which is unique to the Bocavirus genus, appears to be critical for optimal viral 
replication, as the NP1 knock-out mutant of MVC suffers from severe impairment of replication. 
A severe cytopathic effect during MVC infection of WRD cells has been documented (209).  
The HBoV genome has been frequently detected worldwide in respiratory specimens 
from children under two years old with acute respiratory illnesses (3, 97, 188). HBoV is 
associated with acute expiratory wheezing and pneumonia (4, 97, 188), and is commonly 
detected in association with other respiratory viruses (97, 188). Further studies are necessary, 
however, to identify potential associations of HBoV infection with clinical symptoms or disease 
of acute gastroenteritis (8, 99). The full length sequence of infectious MVC DNA (Genbank 
accession no.: FJ214110) that we have reported shows 52.6% identity to HBoV, while the NS1, 
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NP1 and VP1 proteins are 38.5%, 39.9% and 43.7% identical to those of HBoV, respectively 
(204). 
The cytopathic effect induced during parvovirus infection has been widely documented, 
e.g., in infections of minute virus of mice (MVM) (25), human parvovirus B19 (B19V) (195), 
parvovirus H-1 (63, 181) and BPV1 (1). In Bocavirus, cell death during BPV1 infection of 
embryonic bovine tracheal cells has been shown to be achieved through necrosis, independent 
of apoptosis(1). B19V-induced cell death of primary erythroid progenitor cells has been shown 
to be mainly mediated by an apoptotic pathway (195), in which the nonstructural protein 11kDa 
plays a key role (38). In contrast, the MVM-induced cytopathic effect has been revealed to be 
mediated by NS1 interference with intracellular CKII signaling (54, 149, 150), a non-apoptotic 
cell death. Oncolytic parvovirus H-1 infections can induce either apoptosis or no-apoptotic cell 
death, depending on the cell type (63, 129). Therefore, the mechanisms underlying parvovirus 
infection-induced cell death vary, although NS1 has been widely shown to be involved in both 
apoptotic and non-apoptotic cell death. The nature of the cytopathic effect during Bocavirus 
MVC infection has not been studied.      
Parvovirus replication requires infected cells at the S-phase. Infection of parvovirus has 
been revealed to accompany a cell cycle perturbation that mostly leads to an arrest in the S/G2-
phase or the G2/M-phase during infection (87, 96, 135, 158, 220). MVM NS1 expression 
induces an accumulation of sensitive cells in the S/G2-phase (7, 156, 158). Whether MVC 
infection-induced cell death is accompanied by an alternation of cell cycle progression, and 
whether the viral non-structural protein is involved in these processes have not been addressed.      
In this study, we found, in contrast with other members of the family Parvoviridae, 
expression of both the non-structural and structural proteins of MVC by transfection did not 
induce cell death or cell cycle arrest. However, the cytopathic effect induced during MVC 
infection is a replication-coupled, mitochondrion-mediated and caspase-dependent apoptosis, 
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accompanied with a gradual cell cycle arrest from the S-phase to the G2/M-phase, which is 
facilitated by the MVC genome.   
 
Materials and Methods 
Cells and virus:  
 WRD cells (18) were maintained in Dulbecco’s modified Eagle’s medium with 10% fetal 
calf serum in 5% CO2 at 37°C. The MVC used in this study, the original strain GA3, was isolated 
at the School of Veterinary Science, Cornell University. MVC was cultured and quantified as 
previously described, and the virus titer was determined as the number of fluorescence-foci 
forming units (ffu) per ml (21). The WRD cell line and MVC were obtained as gifts from Dr. 
Parrish (Cornell University). 
MVC was inactivated by UV irradiation as follows: In each well of a 96-well plate, 50 µl of 
purified MVC (204) containing the cell culture medium was added. The plate was placed in a 
Hoefer UVC 500 Ultraviolet Crosslinker (Hoefer Inc.) for UV irradiation at a dose of 720 mJ/cm2 
(74, 119).  
  
Infection and transfection:  
WRD cells were seeded one day prior to infection or transfection. MVC at indicated 
multiplicity of infection (MOI= ffu/cell) was added to the culture right after the medium was 
refreshed. 
Transfection was performed using the LipoD293 transfection reagent (SignaGen 
Laboratories, MD) following the manufacturer’s instructions.   
 
Plasmid constructs:  
All the nucleotide (nt) numbers of MVC refer to the MVC GA3 isolate (Genbank 
accession no.: FJ214110).   
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(i) Constructs for expressing non-structural proteins:  The NS1 ORFs (nt 403-2724), 
NP1 ORF (nt 2537-3094) and VP1 ORF (nt 3081-5192) were inserted separately into 
BamHI/XhoI-digested pcDNAGFP vector (19) to construct the pGFP-NS1, pGFP-NP1 and 
pGFP-VP1, respectively. pMVCNSCap was constructed by inserting the MVC sequence of nt 
150-5305 into SacII-ApaI-digested pBluescript SK(+) (Strategene).   
(ii) Mutants of infectious clone pIMVC: The MVC infectious clone, pIMVC, and its 
derivative pIMVCNS1(-), pIMVCNP1(-),  pIMVCVP1(-) and pIMVCVP2(-) were described 
previously (60). pIMVCVP1/2(-) was constructed by combing the VP1 and VP2 ATG mutations 
in pIMVC. pIMVCΔ1/2LTR was constructed by deleting the MVC sequences of nt 1-101 in the 
left palindromic repeat of the pIMVC through NotI digestion.           
(iii) Constructs for glutathione S-transferase (GST)-fusion expression: The MVC 
NP1 ORF (nt 2537-3094) was cloned into pGEX4T3 (GE Health) as pGEX-MVCNP1.  
   
Antibodies:    
   GST-fused MVC NP1 protein was expressed from pGEX-MVCNP1-transformed 
Escherichia coli BL21 cells and purified as described previously (60). The anti-NP1 antiserum 
was produced by immunizing animals with purified GST-MVCNP1 following a protocol described 
previously (60). The animal protocol used was approved by the KUMC Institutional Animal 
Care and Use Committee. 
 Anti-Bax, anti-cyclin B1, anti-phospho-cdc2 (pY15) and anti-cyclin A were purchased 
from BD Biosciences. Anti-β-actin (clone AC-15) was purchased from Sigma. We used dilutions 
of antibodies for Western blotting and immunofluorescence as suggested in the manufacturers’ 
instructions.   
  
SDS-PAGE, Western blotting and immunofluorescence:  
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SDS-PAGE, Western blotting and immunofluorescence assay were performed as 
previously described (27,50,60). Mitochondria were stained by incubating cells with a 
mitochondrion-staining specific dye, MitoTracker Red CMXRos (Invitrogen), at 500 nM in the 
cell culture medium for 30 min before fixation in ice-cold acetone. Confocal images were taken 
at a magnification of 60 × (objective lens) with an Eclipse C1 Plus confocal microscope (Nikon) 
controlled by Nikon EZ-C1 software.   
 
Southern blotting: 
WRD cells were transfected with the MVC constructs as shown in Fig. 3-3C. At 48 h 
posttransfection, low-molecular-weight DNA (Hirt DNA) was extracted from transfected cells as 
described previously (27). Southern blotting was performed as described previously (48) using 
the MVC NSCap probe (60).   
 
Flow cytometry analysis: 
AnnexinV/Propidium Iodide (PI) staining: Cells were dissociated by 0.25% trypsin in 
Versene buffer. The cells were recovered in culture medium at 37°C for 30 min with agitation 
prior to staining, then washed twice with AnnexinV binding buffer. Of these cells, 1 × 106 were 
resuspended in 100 µl of AnnexinV binding buffer, followed by the addition of 5 µl Cy5-
conjugated AnnexinV (BD Biosciences) and 5 µl Propidium Iodide (PI) (60 µg/ml, Sigma). The 
mixture was then incubated at room temperature (RT) for 15 min, followed by the addition of 
400 µl AnnexinV binding buffer. Flow cytomerty was performed after staining.   
FLICA (Fluorochrome-labeled Inhibitor of Caspase) assay and FLICA/Live-Dead 
Violet co-staining:  Cells were dissociated by 0.25% trypsin in Versene and stained with 
carboxyfluorescein(FAM)-labeled FLICA peptides( Immunochemistry Tech, MN), FAM-VAD-
FMK (Poly-FLICA), FAM-DEVD-FMK (Caspase-3&7 FLICA), FAM-VEID-FMK (Caspase-6 
FLICA), FAM-LETD-FMK (Caspase-8 FLICA), FAM-LEHD-FMK (Caspase-9 FLICA), FAM-
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AEVD-FMK (Caspase-10 FLICA) and the fluorescein isothiocyanate(FITC)-labeled FLICA 
peptide (Biovision), FITC-ATAD-FMK (Caspase-12 FLICA), as described previously (20). 
For FLICA/Live-Dead Violet co-staining, cells were stained with FAM-VAD-FMK (poly-
FLICA peptide) followed by Live-Dead Violet staining (Invitrogen) according to the 
manufacturer’s instructions. Specifically, 2 µl of poly-FLICA reagent was added into 300 µl of 
cell suspension [106 cells/ml in phosphate-buffered saline (PBS) containing 2% fetal calf serum 
(PBS-2%FCS)], which was incubated at 37°C for 1 hr. The cells were washed once by PBS-
2%FCS and resuspended in of 500 µl of PBS-2%FCS with 1 µl of Live-Dead Violet dye. The 
mixture was kept on ice for 30 min. Cells were then washed twice with PBS-2%FCS, and fixed 
in 1% paraformaldehyde for 30 min before analysis. For co-staining with anti-NS1 of MVC, fixed 
cells were permeabilized in PBS-2%FCS containing 0.2% Tween-20 (PBST) for 30 min, stained 
with a 1: 50 dilution of anti-NS1 antiserum, followed by staining with a Cy5-labeled secondary 
antibody.   
DAPI staining:  Cells were dissociated by 0.25% trypsin in Versene and fixed in 1% 
paraformaldehyde at RT for 30 min. The cells were washed, stained with DAPI, 4',6-diamidino-
2-phenylindole, at 20 µg/ml in PBST, and then analyzed by flow cytometry. When co-staining 
was required, cells were first stained with anti-NS1 or anti-NP1 followed by DAPI staining.  
Cell proliferation assay (DDAO staining): DDAO, 7-hydroxy-9H-(1,3-dichloro-9,9-
dimethylacridin-2-one), a fixable, far-red-fluorescent tracer for very long-term cell labeling, was 
purchased from Invitrogen and applied following the manufacturer’s instructions. Briefly, every 5 
million cells were collected and washed twice with pre-warmed PBS. The cells were then 
resuspended in 1 ml of 10 µM DDAO in PBS and kept at 37°C for 10 min. The mixture was then 
immediately transferred to 15 ml of pre-warmed cell culture medium to quench the reaction. 
After cells were washed twice with the warmed medium, they were then resuspended in the 
medium, and incubated at 37°C. The next day, stained cells were used either for MVC infection 
or transfection. When required, DDAO-stained cells were fixed and further stained intracellularly 
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with anti-NS1. DDAO fluorescence decays when cells proliferate; therefore, the lower the 
fluorescence detected, the better the proliferation of cells (Fig. 3-3-1D&4D).  
MOMP (Mitochondrial Outer Membrane Permeabilization) detection [DiIC1(5)/PI or 
poly-FLICA co-staining]: The level of MOMP was determined by the MitoProbe DiIC1(5) Assay 
Kit (Invitrogen). DiIC1(5) (1’,1’,3,3,3’,3’-hexamethylindodicarbo-cyanine iodide) accumulates 
primarily in mitochondria with active mitochondrial membrane potentials. DiIC1(5) staining 
decreases as the mitochondrial membrane potential is reduced. Cell membrane permeability 
was probed by propidium iodide (PI, Sigma). Co-staining of DiIC1(5) with PI was performed 
following the manufacture’s instruction (Invitrogen). Briefly, WRD cells were trypsinized and 
resuspended at 106 cells/ml of the cell culture medium, into which 5 µl of DiIC1(5) at 10 µM in 
DMSO (dimethyl sulfoxide) was added, followed by incubation at 37°C for 15 min. PI was added 
to the mixture to a final concentration of 0.3 µg/ml. The mixture was then incubated for another 
15 min at 37°C. For co-staining with poly-FLICA peptide, cells were stained with ploy-FLICA for 
30 min at 37°C prior to the addition of DiIC1(5), then incubated at 37°C for another 30 min. 
CCCP(carbonyl cyanide 3-chlorophenylhydrazone) was used as a positive control for disrupting 
mitochondrial outer membrane potential at a final concentration of 50 µM. The stained cells 
were analyzed on a flow cytometer.  
All the samples were analyzed on a three-laser flow cytometer (LSR II, BD Biosciences) 
within an hour of staining at the Flow Cytometry Core of the University of Kansas Medical 
Center. All flow cytometry data were analyzed using FACS DIVA software (BD Biosciences).   
   
Results  
MVC infection induces cell death and cell cycle arrest in WRD cells.  
 To analyze cell death and cell cycle arrest induced during MVC infection, we infected 
WRD cells with MVC and stained them with anti-NS1, Live-Dead Violet and FAM-VAD-FMK 
(poly-FLICA peptide) at the indicated times p.i. We selected the MVC-infected cells, which were 
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anti-NS1 positive, and plotted as Live-Dead Violet fluorescence vs. FLICA fluorescence intensity 
in Fig. 3-3-1A. MVC infection induced a cell death in a time-dependent manner during infection 
as shown by the Live-Dead Violet staining. From 18 to 96 hrs p.i., the live cell population (Live-
Dead¯) decreased from 91.7% to 45.2% (Fig. 3-3-1A, Control). In addition, dead cells (Live-
Dead+) in the control group were almost all stained with FAM-VAD-FMK (poly-FLICA+), 
indicating that caspases were activated in all the dead cells (Fig. 3-3-1A, Control). Active 
caspase is a hallmark of apoptotic cell death (61). This result indicates that MVC infection 
induces an apoptotic cell death. Moreover, with the addition of a specific pan-caspase inhibitor, 
Q-VD-OPH (Q-VD), cell death in MVC-infected cells was inhibited even at 96 hrs p.i. (Fig. 3-3-
1A, Q-VD). Q-VD is a newly developed pan-caspase inhibitor without significant cross reactivity 
with cathepsin (35). Thus, the rescue of cell death by Q-VD further confirmed the apoptotic 
nature of MVC infection-induced cell death.  
  MVC infection not only induced apoptosis, but also a severe cell cycle arrest of infected 
WRD cells. We gated MVC NS1-expressing cells and plotted them in the histogram of DAPI 
staining (Fig. 3-3-1B).  Cell cycle analysis of MVC-infected cells by DAPI staining showed a 
clear transition from an S-phase accumulation to a G2/M arrest during MVC infection (Fig. 3-3-
1B). As early as 18 hrs p.i., we observed a widened peak with apex in the S-phase (Fig. 3-3-1B, 
18 hrs p.i.). Only 6 hrs later, the S-phase accumulation became weaker and was replaced by 
G2/M arrest at 24 hrs p.i. (Fig. 3-3-1B, 24 hrs p.i.). After that, the cell cycle of NS1-expressing 
cells was mostly seized in the G2/M-phase (Fig. 3-3-1B, 48, 72 and 96 hrs p.i., respectively). 
The Q-VD treatment, while completely abolishing the apoptosis induced by MVC infection (Fig. 
3-3-1A, Q-VD), did not change the cell cycle perturbation (data not shown). To further support 
the observation that MVC infection induced cell cycle arrest, we used Western blotting to probe 
the level of cell cycle regulatory proteins, cyclin B1, phospho-cdc2 (pY15) and cyclin A. As 
shown in Fig. 3-3-1C, G2/M-phase checkpoint regulators, cyclin B1 and phospho-cdc2 (pY15), 
were both upregulated at 24  
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Figure 3-1. MVC infection induces apoptosis and cell cycle arrest.  
WRD cells were infected with MVC at an MOI of 3. (A) Cells were cultured in media 
supplemented with DMSO as a control or a pan-caspase inhibitor Q-VD (R&D Systems) at 40 
µM immediately after infection. At indicated times p.i., infected cells were triple stained by anti-
NS1, Live-Dead Violet and poly-FLICA. Anti-NS1-stained cells were selected and plotted as 
Live-Dead Violet vs. poly-FLICA florescence. The percentage of live cells (double negative) is 
shown in the square gate. (B) At the indicated times p.i., cells were double stained by anti-NS1 
and DAPI. The anti-NS1-stained cells were selected and plotted as cell counts vs. DAPI 
staining. Percentages of cells at G0/G1-, S- and G2/M-phase are shown in circle graphs at the 
bottom of the panel. (C) Mock and MVC-infected WRD cells were harvested at 24 hrs and 48 
hrs p.i., respectively. Cell lysates were subjected to Western blotting using anti-cyclin B1, anti-
cdc2(pY15), anti-cyclin A and anti-β-actin, respectively. The levels of signals on blots, which are 
normalized to the level of β-actin, are shown in the bar chart to the right. The normalized value 
of the mock cells at 24 hrs is arbitrarily set to 1. (D) At 24 hrs and 48 hrs p.i., MVC- infected 
WRD cells were stained with DDAO and anti-NS1. Both anti-NS1 positive (NS1+) and negative 
[NS1(-)] populations were gated and plotted as histograms of cell counts vs. DDAO signal. 
Numbers as shown are percentage of proliferated cells. The line as shown is arbitrarily set 
based on the non-proliferated control cells, which were fixed immediately after infection.  
A representative of two independent experiments is shown in panels A-D. 
69 
 
70 
 
and 48 hrs p.i. in MVC-infected cells. Cyclin A, which is required for S-phase passage, did not 
differ significantly between mock- and MVC-infected cell groups.  
We next stained MVC-infected cells with DDAO to evaluate cell proliferation. Consistent 
with the cell death and cell cycle arrest induced during MVC infection, NS1-expressing cells 
showed a severely impaired proliferation of approximately 4-fold compared with NS1-negative 
cells both in early infection ( 3.8% vs. 25.1% at 48 hrs p.i.) and later infection (18.8% vs. 78.9% 
at 72 hrs p.i.)  [Fig. 3-3-1D, compare groups NS(-) with NS+].   
Taken together, these results show that MVC infection induces an apoptotic cell death 
and a perturbation of cell cycle progression from the S-phase during early infection to the G2/M-
phase during later infection.  
 
MVC infection-induced apoptosis is mitochondrion-mediated. 
We next sought to examine the potential activation of the mitochondrion-mediated 
apoptotic pathway in MVC infection-induced apoptosis. During mitochondrion-mediated 
apoptosis, the proapoptotic protein Bax translocalizes to the mitochondrion outer membrane to 
trigger the permeabilization of the outer membrane, which in turn results in cytochrome c 
release and downstream caspase activation (103). We first employed the MitoProbe™ DiIC1(5) 
to directly probe the level of mitochondrion outer membrane permeabilization (MOMP). During 
MVC infection, the degree of MOMP occurred in a time-dependent manner (Fig. 3-3-2A). NS1-
expressing cells showed a clear transition from DilC1(5)high/PI¯ (Live) to  
DilC1(5)low/PI¯(Early/Middle apoptotic ) and to DilC1(5)low/PI+ (Late apoptotic/Dead) populations 
during infection from 48 to 96 hrs p.i. The DilC1(5)low/PI¯ population represents cells in which the 
mitochondrial outer membrane is disrupted but the cell membrane is intact,  while the 
DilC1(5)low/PI+ population represents cells in which both the mitochondrial outer membrane and 
the cell membrane are disrupted. This result indicated that MOMP precedes cell death during 
MVC infection.  
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Figure 3-2. MVC infection-induced apoptosis is mitochondrion-mediated.  
WRD cells were infected with MVC at an MOI of 3. (A)  MVC-infected cells were 
harvested at indicated times p.i., and double stained with PI and DilC1(5). A mock infection 
control and a MOMP-positive control (CCCP-treated cells) were included. Stained cells were 
thereafter analyzed by flow cytometry and plotted as PI staining vs. DilC1(5) staining. The 
DilC1(5)high/PI¯ (Blue) population represents live cells; DilC1(5)low/PI¯ (Green) cells are in the 
early and middle stages of apoptosis; DilC1(5)low/PI+ (Red) are late-apoptotic or dead cells. The 
percentage of each cell population is shown in color. A representative of two independent 
experiments is shown. (B) MVC-infected WRD cells, at 96 hrs p.i., were double stained with 
poly-FLICA and DilC1(5). A representative dot plot is shown. The  DilC1(5)high/FLICA¯ (Blue) 
population represents live cells; DilC1(5)low/FLICA¯ (Green) population are cells in the initial 
stage of apoptosis ; DilC1(5)low/FLICA＋ (Red) population are both apoptotic and dead cells. The 
percentage of each cell population is shown in color. (C) At 48 hrs p.i., mock or MVC-infected 
WRD cells were stained with MitoTracker Red (Red) and anti-Bax (Green). Representative 
confocal images were taken. Nuclei were stained with DAPI. (D) At the indicated times p.i., 
MVC-infected WRD cells were stained with anti-NS1 and various FLICA peptides as shown. 
Anti-NS1-stained cells were selectively gated and plotted in histogram form to show the FLICA 
signals of NS1-expressing cells. Mock cells were all plotted as poly-FLICA staining. The 
percentage of FLICA positive cells is shown. A representative of two independent experiments 
is shown.  
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We also co-stained MVC-infected cells with FAM-VAD-FMK (poly-FLICA) and DilC1(5) at 96 hrs 
p.i. The NS1-expressing cells showed three distinct populations as DilC1(5)high/FLICA¯ (Non-
apoptotic), DilC1(5)low/FLICA¯ (Apoptosis initiating) and DilC1(5)low/FLICA+ (Apoptotic), 
respectively (Fig. 3-3-2B). The DilC1(5)low/FLICA¯ population represents cells in which the 
mitochondrial outer membrane is disrupted but caspases have not yet been activated, while the 
DilC1(5)low/FLICA+ population represents cells with both a disrupted mitochondrial outer 
membrane and activated caspases. This result supports that a transition occurs from DilC1(5) 
staining to poly-FLICA staining in NS1-expressing cells. Collectively, these results suggest that 
MOMP precedes caspase activation and cell death during infection. The fact that caspases are 
activated in the same population of cells with MOMP is consistent with mitochondrion-mediated 
apoptosis. 
To further confirm that MVC infection-induced apoptosis is mitochondrion-mediated, we 
used anti-Bax staining and a mitochondrion-specific MitoRed staining to probe whether the Bax 
localizes on the mitochondrial outer membrane. We observed a precise colocalization of the 
anti-Bax staining (Green) with the MitoRed staining in MVC-infected cells at 48 hrs (Fig. 3-3-2C, 
MVC). In contrast, Bax dispersed in the uninfected cells (Fig. 3-3-2C, Mock). This result 
indicates translocation of the Bax to the mitochondrial outer membrane of MVC-infected cells 
during infection, which presumably triggers disruption of the mitochondrial outer membrane 
potential that in turn activates caspases.  
To confirm activation of individual caspases during infection, we used poly- and 
individual caspase FLICA assays to determine the level of activated caspases of NS1-
expressing cells. Activation of caspases increased from 48 hrs, 72 hrs and 96 hrs p.i.; however, 
at all three time points, similar patterns of caspase activation were detected (Fig. 3-3-2D). 
Among all the caspases tested, caspase-6, -8 and -9 were the most activated, followed by 
caspase-3/7, -10 and -12 (Fig. 3-3-2D). At 96 hrs p.i., while poly-FLICA showed an overall 
active caspase-positive rate of 58%, caspase-6, -8 and -9 were activated at a rate of 53%, 53% 
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and 56% of NS1-expressing cells, respectively (Fig. 3-3-2D, 96 hrs). Active caspase-3/7, -10 
and -12 were only detected in 40%, 43% and 48% of NS1-expressing cells, respectively. The 
extensive activation of caspase-9 is further an evidence that supports the mitochondrion-
mediated apoptosis induced during MVC infection.  
  
Replication of the MVC genome induces caspase activation.  
Next, we sought to explore which vial components were involved in MVC infection-
induced apoptosis and cell cycle arrest. We transfected the MVC infectious clone, pIMVC, its 
derivatives pIMVCNS1(-), pIMVCNP1(-), pIMVCVP1(-), pIMVCVP2(-), pIMVCVP1/2(-) and 
pIMVCΔ1/2LTR, and MVC NSCap gene-containing pMVCNSCap into WRD cells, separately. At 
48 hrs posttransfection, we analyzed transfected cells for apoptosis and cell cycle by poly-
FLICA and DAPI staining, respectively, and co-stained cells with anti-NS1 except for 
pIMVCNS1(-)-transfected cells, which were co-stained with anti-NP1. The NS1-expressing or 
NP1-expressing cells were then selected and plotted for FLICA or DAPI florescence intensity for 
comparison (Fig. 3-3A&B).  
Transfection of pIMVC induced 22% poly-FLICA+ population in NS1-expressing cells at 
48 hrs posttransfection (Fig. 3-3A, pIMVC). The NS1 knock-out construct, pIMVCNS1(-), which 
is replication-deficient (204), generated only 5.4% poly-FLICA+ population [Fig. 3-3A, NS1(-)]. 
However, transfection of the NS(-) mutant did express NP1 that was used to select positive 
transfected cells, suggesting only expression of the NP1 does not activate caspases. The NP1 
knock-out construct, pIMVCNP1(-), which replicates poorly(204), generated 9.8% poly-FLICA+ 
population [Fig. 3-3A, NP1(-)]. Regardless of whether VP1, VP2 or both were knocked out, 
replication of the MVC genome was detected in pIMVCVP1(-), pIMVCVP2(-) (204) and 
pIMVCVP1/2(-)-transfected cells [Fig. 3-3C, VP1(-) and VP1/2(-)]; correspondingly, an average 
of 17% of FLICA+ populations were detected in transfected cells [Fig. 3-3A, VP1(-), VP2(-) and 
VP1/2(-)]. Transfection of the half left terminal repeat (LTR)-deleted mutant, pIMVCΔ1/2LTR, of  
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Figure 3-3. Replication of the MVC genome activates caspases and the MVC genome per 
se arrests cell cycle at the G2/M-phase.  
WRD cells were transfected with plasmids as shown. (A) At 48 hrs posttransfection, 
transfected cells were co-stained with anti-NS1, except for pIMVCNS1(-)-transfected cells, 
which were co-stained with anti-NP1, and poly-FLICA peptide. The anti-NS1 positive or anti-
NP1 positive population was selectively gated and plotted as cell counts and FLICA signal. The 
percentage of FLICA positive cells is shown as an average with a standard deviation generated 
from three independent experiments. (B) At 48 hrs posttransfection, transfected cells were co-
stained with anti-NS1, except for pIMVCNS1(-)-transfected cells, which were co-stained with 
anti-NP1, and DAPI. Anti-NS1- or anti-NP1-stained cells were selectively gated and plotted as 
cell counts and DAPI signal. The percentage of each cell cycle phase was quantified and is 
shown as a pie graph at the bottom of the panel. A representative of two independent 
experiments is shown. (C) Southern blotting analysis of transfected WRD cells. At 48 hrs 
posttransfection, transfected cells were harvested and Hirt DNA was prepared. Hirt DNA was 
then digested with DpnI. The blot was probed with the NSCap probe as previously described 
(60). Detected bands are indicated with their respective designations to the left. Lanes 1, 10 and 
15 are size markers of 5.15 kb. RF: replicative form; dRF: double replicative form.      
76 
 
77 
 
which replication was decreased (Fig. 3-3C, Δ1/2LTR), induced a reduced level, 14%, of poly-
FLICA+ population (Fig. 3-3A, Δ1/2LTR). Transfection of the NSCap gene-containing construct, 
pMVCNSCap, which did not replicate (Fig. 3-3C, NSCap), failed to induce a significant level of 
poly-FLICA+ population compared with the control (Fig. 3-3A, NSCap). However, transfection of 
the pMVCNSCap expressed NS1, which was used to select positive transfected cells, and NP1 
(Fig. 3-5B), suggesting that only expression of the NS1 and NP1 without replication of the 
genome does not activate caspases.   
The VP1(-) and VP2(-) mutants have been shown to knock out VP1 and VP2 expression 
by a single burst replication of the viral genome(204). Transfection of the combined VP1/2(-) 
mutant resulted in a single burst replication compared with transfection of the VP1(-) mutant [Fig. 
3-3C, compare VP1/2(-) with VP1(-)]. These results suggest that without expression of the VP1 
and VP2 only replication of the MVC genome is sufficient to activate caspases.  
 Replication efficiency of these transfected constructs as shown by Southern blots was 
ranked as pIMVC > pIMVCVP1(-), pIMVCVP2(-) and pIMVCVP1/2(-) > pIMVCΔ1/2LTR > 
pIMVCNS1(-) and pMVCNSCap (Fig. 3-3C). Thus, the efficiency of replication seems to 
correlate directly with the level of caspase activation. Collectively, these results reveal that 
activation of caspases, as assayed by poly-FLICA, of transfected cells is associated with 
replication of the MVC genome, rather than the expression of the MVC NP1 and VP1/VP2 
capsid proteins.   
 
The MVC genome per se arrests cell cycle at the G2/M-phase.  
With DAPI-staining, we further examined the capability of inducing cell cycle arrest 
through transfection of these MVC constructs. Transfection of the infectious clone (pIMVC) 
induced a scenario of cell cycle arrest at the G2/M-phase similar to that of MVC-infected cells 
with a transition of S-phase accumulation (Fig. 3-3B, pIMVC). Surprisingly, at 48 hrs 
posttransfection, cells transfected with pIMVCNS1(-), pIMVCNP1(-), pIMVCVP1(-), pIMVCVP2(-) 
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and pIMVCVP1/2(-), which all contain terminal repeats at both ends, showed an apparent G2/M 
arrest of approximately 42%, 46%, 45%, 52% and 44%, respectively, in comparison with 19% in 
the control group (Fig. 3-3B). However, no apparent S-phase accumulation was observed in 
cells transfected with the above pIMVC mutants even at earlier time points (data not shown). 
Interestingly, transfection of the left half terminal repeat (TR)-deleted mutant, pIMVCΔ1/2LTR, 
still induced a G2/M arrest of 46% (Fig. 3-3B, Δ1/2LTR); however, transfection of the TRs-
deleted mutant, pMVCNSCap, failed to induce G2/M arrest in NS1-expressing cells compared 
with the control (Fig. 3-3B, NSCap).  
Together with those results from Southern blotting analysis (Fig. 3-3C), our observations 
suggest that the terminal repeats of the MVC genome are required to induce cell cycle arrest at 
the G2/M-phase, and replication of the genome and expression of the NS1, NP1 and VP1/2 
proteins are dispensable. The S-phase accumulation as seen during MVC infection and 
transfection of the infectious clone may require a status of efficient replication of the viral 
genome.   
  
Expression of MVC individual viral proteins by transfection does not induce cell death or 
cell cycle arrest.   
 To further confirm that MVC proteins are not required to induce apoptosis and cell cycle 
arrest of transfected WRD cells, we transfected WRD cells with a set of constructs expressing 
GFP-fused MVC proteins, the GFP-positive population was selectively gated and quantified by 
AnnexinV staining for apoptosis (38). Not surprising, no significant amount of apoptosis or cell 
cycle disturbance was observed in cells transfected with individual or combined GFP-fused 
MVC protein-expressing constructs in comparison with cells transfected with the GFP control, 
as shown by AnnexinV/PI staining for apoptosis (Fig. 3-4A) and DAPI staining for cell cycle (Fig. 
3-4B&C).  
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Figure 3-4. Expression of individual MVC proteins or in combination by transfection does 
not induce cell death or cell cycle arrest. 
 WRD cells were transfected with various constructs, as shown, that express GFP-fused 
MVC proteins. (A) Transfected cells were co-stained with AnnexinV/PI at 48 hrs posttransfection. 
The GFP-positive population was selectively gated. The percentage of non-apoptotic cells 
(AnnexinV¯/PI¯ population) in the GFP-positive population in each transfection was then 
plotted. All the values were generated from three independent experiments and are shown as 
an average with a standard deviation. (B) Representative results of cell cycle analysis. 
Transfected cells were stained with DAPI at 48 hrs posttransfection. The GFP-positive 
population was selectively gated. The cell cycle analysis results are shown as GFP-negative 
population vs. GFP-positive population, respectively. (C)The percentage of cells at the G0/G1-
phase is shown as an average with a standard deviation obtained from three independent 
experiments. (D) Transfected cells were stained with DDAO at 48 hrs posttransfection. The 
GFP-positive population was selectively gated and plotted. Numbers as shown are percentage 
of proliferated cells. The line as shown is arbitrarily set in the control cells, which were fixed 
immediately after transfection.  
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Expression of these GFP-fused proteins by transfection was confirmed by fluorescence 
microscopy (Fig. 3-5A), approximately 10% of WRD cells were GFP-positive. GFP-NS1 and -
NP1 showed a similar nucleus-localization as that of the wild type NS1 and NP1 expressed from 
the transfection of pMVCNSCap in WRD cells (Fig. 3-5B), while transfection of the GFP-VP1 
showed localization mostly in the nucleus with somewhat diffusion in the cytoplasm (Fig. 3-5A). 
Interestingly, during MVC infection, the NS1 was localized in distinct replication center-like foci 
(Fig. 3-5B, MVC/α-NS1), similar to that of other parvoviruses (9,59), while the NP1 showed a 
unique peri-nucleus localization (Fig. 3-5B, MVC/α-NP1). The pattern of NS1 localization was 
also observed in cells transfected with replicative pIMVC and pIMVCVP1/2(-) (Fig. 3-5B). We 
speculate that the unique localization of the NS1 is due to the replication of the viral genome. 
Transfection of the pIMVCNP1(-) and pMVCNSCap did not show clear NS1-localized foci in the 
nucleus (Fig. 3-5B). We did not observe the peri-nucleus localization of NP1 in cells transfected 
with both replicative and non-replicative MVC constructs (Fig. 3-5B). Thus, we believe that the 
difference of the localization pattern of the NS1 and NP1 in the nucleus is less likely to result in 
the inability of the NS1 and NP1 to induce apoptosis. In addition to these observations, we also 
observed that expression of individual GFP-fused MVC proteins or those combined by 
transfection did not inhibit cell proliferation compared with the control GFP transfection group 
(Fig. 3-4D).   
Collectively, our results suggest that unlike the non-structural proteins of other 
parvoviruses, the MVC proteins, especially the NS1 and NP1, expressed by transfection of 
WRD cells, do not induce an apparent cell death or a perturbation of cell cycle progression.    
   
UV-inactivated MVC induces cell cycle arrest but not cell death.  
 To further confirm the role of the MVC genome in inducing apoptosis and cell cycle 
arrest, we inactivated purified MVC by UV irradiation. WRD cells were either infected with 
untreated (MVC) or inoculated with UV-irradiated MVC (UV-MVC). Apoptosis and cell cycle  
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Figure 3-5. Cellular localization of MVC proteins during infection and in transfection.  
(A) WRD cells were transfected with constructs expressing GFP-fused MVC proteins as 
shown. Cells were treated at 48 hrs posttransfection. (B) WRD cells were infected with MVC at 
an MOI of 3 or transfected with the MVC constructs as indicated. At 48 hrs p.i. or 
posttransfection, cells were stained with anti-NS1 and anti-NP1, respectively. Confocal images 
were taken at × 60 magnification. Nuclei were stained with DAPI.    
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Figure 3-6. UV-MVC inoculation induces cell cycle arrest at G2/M but not cell death. 
 WRD cells were infected by MVC or inoculated with UV-MVC at an MOI of 9. (A) 
Infected or inoculated cells were co-stained with Live-Dead Violet and poly-FLICA peptide at 
indicated times p.i. Stained cells were plotted in histograms as Live-Dead Violet and FLICA 
signals. The numbers in the square show percentages of live cells (double negative). (B) At 48 
hrs p.i., mock or UV-MVC-infected cells were stained with DAPI and plotted as cell counts and 
DAPI signal. The percentage of each cell cycle phase was quantified and is shown as a pie 
graph at the bottom of the panel. (C) UV-MVC-infected cells were harvested at indicated times 
p.i. Cell lysates were subjected to Western blotting analysis using anti-cyclin B1, -cdc2 (pY15), -
cyclin A and -β-actin, respectively. The level of signals on blots is normalized to the level of β-
actin and is shown in the bar chart. The normalized value of the mock cells is arbitrarily set to 1.  
A representative of two independent experiments is shown in panels A&B. 
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status were evaluated by Live-Dead Violet/FLICA co-staining and DAPI staining, respectively. 
Since NS1 was not expressed in WRD cells inoculated with UV-MVC (data not shown), we used  
an MOI of 9 for inoculation. We gated total cells and plotted them in Fig. 3-6A&B. At this MOI, 
MVC infection induced apoptosis more drastically, which was observed as early as 18 hrs p.i. 
and progressed over the course of infection (Fig. 3-6A, MVC). At 48 hrs p.i., only 46% of MVC-
infected cells were still alive (Live-Dead Violet¯/FLICA¯). In contrast, UV-MVC inoculation failed 
to induce a significant level of cell death at all three times p.i. (Fig. 3-6A, UV-MVC)   
Meanwhile, we compared the cell cycle regulation of MVC-infected and UV-MVC-
inoculated WRD cells at the same MOI. Consistent with the findings shown in Fig. 3-3-1B, the 
S-phase accumulation transitioned to the G2/M arrest during MVC infection (Fig. 3-6B, MVC). 
While most of the WRD cells were at the S-phase at 18 hrs p.i., the majority of MVC-infected 
cells were arrested at the G2/M-phase at late time points. Interestingly, UV-MVC induced a 
significant cell cycle arrest at G2/M as early as 18 hrs p.i. (Fig. 3-6B, UV-MVC). Consistent with 
the transfection experiments shown in Fig. 3-3, we did not observe an S-phase accumulation 
during UV-MVC inoculation (Fig. 3-6B). Moreover, to confirm the G2/M arrest induced by UV-
MVC inoculation, we determined the protein level of the G2/M-phase checkpoint regulators in 
UV-MVC-inoculated cells. A significant increase of both cyclin B1 and cdc2 (pY15) was 
observed at both 18 and 24 hrs p.i. (Fig. 3-6C). However, the fold of increase was less than that 
of the MVC-infected cells shown in Fig. 3-3-1C. The level of cyclin A remained unchanged in 
UV-MVC inoculated cells.  
Collectively, these lines of evidence further support that the MVC viral genome alone 
can induce cell cycle arrest at the G2/M-phase, but not the S-phase accumulation or cell death.  
  
Discussion 
Bocavirus MVC infection induces a mitochondrion-mediated apoptosis: Parvovirus 
infection often causes cell death of infected cells either by apoptosis or by various mechanisms 
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of non-apoptotic cell death. Novel mechanisms of non-apoptotic cell death induced by 
parvovirus infection have been revealed recently. MVM infection-induced cell death is mediated 
by NS1 interference with intracellular CKII signaling (54, 149, 150). On the other hand, 
parvovirus H-1 can induce a non-apoptotic cell death of glioma cells that is dependent on 
accumulation of cathepsin B/L (63). However, the mechanisms underlying parvovirus infection-
induced apoptosis have not been elucidated in detail. Apoptosis is defined mechanistically as 
three pathways of regulated cell death involving the sequential activation of caspases, the 
extrinsic pathway is involved in the engagement of particular “death” receptors (e.g., Fas) and 
through the formation of the death-inducing-signaling-complex (DISC) (9). The mitochondrion-
mediated (intrinsic) pathway is activated by “BH3-only” proteins such as tBid, Bad, Bim and 
PUMA; these activated proteins are subsequently translocated to the mitochondrial membrane, 
where they activate the proapoptotic proteins, Bax and Bak (103). Bax/Bak activation results in 
mitochondrial outer membrane permeabilization (MOMP), with consequent release of 
cytochrome c and other mitochondrial proteins with the consequent activation of caspase-9 (40). 
Activated caspase-8/-10 is also able to cleave Bid to tBid which activates Bax/Bak. In 
endoplasmic reticulum (ER)-stress-mediated apoptosis, caspase-12 is localized to the ER and 
activated by ER stress (141).  
We have shown in our studies that MVC infection induces an apoptotic cell death, 
represented by the presence of activated caspases in infected cells. Consistently, the specific 
pan-caspase inhibitor Q-VD completely blocked MVC infection-induced cell death. Moreover, 
the translocalization of the proapoptotic Bax to the mitochondrial outer membrane and 
consequently the time-dependent disruption of mitochondrial outer membrane potential 
indicated the activation of mitochondrion-mediated apoptosis during MVC infection. This 
mechanism is further supported by the extensive activation of caspases, especially the activated 
caspase-9, during MVC infection. We also detected the activation of the initiator caspase-8, -10 
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and -12; however, whether the extrinsic pathway or the ER-stress-mediated pathway is also 
involved in MVC infection-induced apoptosis to some extent warrants further investigation.      
Replication of the viral genome induces apoptosis of MVC-infected cells: In our 
results, expression of the non-structural protein NS1 and NP1 of MVC did not induce cell death 
in transfected cells, which contrasts with the function of the large nonstructural protein of other 
parvoviruses, e.g., the NS1 of MVM (44), H-1 (52) and B19V (58), the Rep78 of AAV2 (56), and 
the small nonstructural protein 11kDa of B19V (16). Thus, our results suggest that the non-
cytotoxic nature of the MVC NS1 is novel in parvoviruses, and might be a general feature of the 
NS1 among other members in the genus Bocavirus. 
Surprisingly, our studies showed that activation of caspases coincided with the 
replication of the viral gnome. The efficiency of replication correlated well with the level of 
caspase activation in cells transfected with pIMVC and its mutants (Fig. 3-3A&C). In the 
scenario in which replication of the MVC genome occurs either during MVC infection or in 
transfection of the replicative MVC constructs, apoptosis is induced in infected or transfected 
cells. However, when DNA replication is abolished either by knocking out NS1 expression or 
deleting both terminal repeats, transfection of these non-replicative mutants does not induce 
apoptosis. When DNA replication is significantly reduced either by knocking out the NP1 
expression or deleting the left half terminal repeats, transfection of these replication-reduced 
mutants induces a decreased degree of apoptosis. These observations strongly suggest that 
the apoptosis induced from transfection of the MVC infectious clone and its replicative 
derivatives is dependent on the replication of the MVC genome. We know that only expression 
of the viral proteins by transfection (Fig. 3-4) does not induce apoptosis; however, NS1 is 
essential for the replication of the viral genome. Thus, we cannot rule out an indirect role of the 
NS1 in inducing apoptosis during MVC infection.     
It is reasonable to speculate that a DNA damage response could be induced in WRD 
cells upon MVC infection or simply by replication of the viral genome. A DNA damage response 
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induced by AAV2 infection has been extensively explored (51,61,64). AAV2 DNA, which is 
single stranded with hairpin loops at both ends, can be sensed as abnormal DNA by the cell, 
triggering a DNA damage response independent of p53 (51). We have evidence that MVC 
infection induced a DNA damage response represented by phosphorylation of H2AX, p53 and 
ATM (data not shown). DNA damage response induces apoptosis when the damage is not 
repairable through upregulation of the proapoptotic proteins such as tBid, Fas, Bax or PUMA 
(5,35,54). It is also possible that an initial DNA damage response induced by the MVC genome 
incurs cell cycle arrest, and later, during viral DNA replication, accumulated MVC genomes 
trigger an irreversible DNA damage response that results in apoptotic cell death. On the other 
hand, the DNA damage response signals the DNA repair machinery, which may be helpful in 
replicating the single stranded genome of MVC. These novel mechanisms have never been 
studied in autonomous parvovirus infection and warrants further investigation. Therefore, we 
have provided an excellent model to study how the viral genome and its replication induce 
cellular responses that favor virus DNA replication at an early stage of infection and egress of 
progeny virus at a later stage of infection. The apoptosis induced by replication of the MVC 
genomes may be a common mechanism underlying parvovirus infection-induced apoptosis.   
Bocavirus MVC infection induces cell cycle arrest:  Parvovirus infection induces cell 
cycle arrest (30,33,42,47,65) most often at the S/G2-phase, which favors virus DNA replication. 
However, a G2/M-phase arrest is clearly observed as early as 6 hrs after B19V infection (42). 
Nevertheless, we have shown here that MVC infection incurs an apparent S-phase 
accumulation at early infection followed by an arrest of the G2/M phase in late infection (Fig. 3-
3-1). The DAPI staining in our study presents the authentic cell cycle of host cells. We quantified 
the MVC genomic copy number per cell at 48 hrs p.i. The genomic copy number per cell, which 
includes the replicative form (RF) DNA of MVC, was approximately 0.1 million, which equals 
0.55 billion bases. The human genome contains approximately 3.4 billion base pairs per cell 
(http://www.genome.gov/18016863). Thus, assuming the canine genome is similar in size to the 
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human genome, the DAPI staining contributed by the replicated MVC genomes and RF DNA is 
less than 8% of the total DAPI staining in an infected cell, which is not sufficient to change the 
pattern of the cell cycle represented by DAPI staining. Based on evidence showing the critical 
cell cycle proteins and inhibition of cell proliferation during MVC infection (Fig. 3-3-1C&D), we 
believe that the DAPI staining presents the authentic cell cycle of MVC-infected cells in our 
studies. 
Cell cycle arrest at the G2/M-phase often precedes the onset of apoptosis (22,31,63). 
We did not observe an apparent G2/M-phase arrest preceding apoptosis during MVC infection. 
In contrast, G2/M arrest by transfection of the NS1-knock-out mutant [pMVCNS1(-)] or UV-
irradiated MVC did not induce apoptosis (Fig. 3-3 and Fig. 3-6), and inhibition of apoptosis by Q-
VD did not release cell cycle arrest (data not shown). Thus, we believe that the cell cycle arrest 
and apoptosis of MVC infection are induced through independent pathways in parallel.  
In transfecting the mutant MVC infectious clones, as shown in Fig. 3-3, we tested cell 
cycle arrest at early time points of transfection. We were not able to detect any S-phase 
accumulation in transfection of these mutants than the infectious clone per se (data not shown). 
Nevertheless, we consistently observed the G2/M arrest at 48 hrs posttransfection in all the 
transfections of the mutant infectious clones that contain the viral terminal repeats. Thus, the S-
phase accumulation appears only when highly efficient replication occurs, e.g., transfection of 
the infectious clone or MVC infection. The S-phase has been emphasized to be important for 
parvovirus replication. For example, parvovirus H-1 protein synthesis coincides with cellular 
DNA synthesis (62), and MVM replication apparently requires mitotically active cells (28).  
Efficient replication of the MVC genome could possibly trigger the S-phase accumulation which 
loops back to further facilitate MVC DNA replication.  
The genome of MVC induces cell cycle arrest at G2/M: Using UV-MVC, we were able 
to show a significant level of G2/M arrest of UV-MVC-inoculated WRD cells as early as 18 hrs 
p.i. UV-MVC infection-induced cell cycle arrest at G2/M is consistent with previous reports of 
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other parvoviruses (41,51,53). The genome of AAV2 that contains an identical inverted terminal 
repeat at both ends has been shown to induce cell cycle arrest at the G2/M-phase (51). 
Infection of UV-irradiated B19V has been shown to induce a G2/M arrest as early as at 24 hrs 
p.i. (41). The G2/M-phase arrest by the MVC genome alone was also reproduced by 
transfection of the NS1 knock-out mutant of the MVC infectious clone. The MVC genome that 
lacks half of the left terminal repeat still induced a clear G2/M arrest by transfection. Only the 
MVC genome that does not contain both terminal repeats, the NSCap gene, lost its ability to 
induce cell cycle arrest. These observations suggest that the terminal repeats of the MVC 
genome, which form strong secondary structures (60), play an important role in inducing cell 
cycle arrest at the G2/M-phase during MVC infection. It may be true that the structure of the 
terminal repeats of parvoviruses acts as a perfect trigger to induce DNA damage response, 
which in turn, induces cell cycle arrest.              
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Chapter 4 
Role of erythropoietin receptor signaling in parvovirus B19 infection 
of human erythroid progenitor cells   
 
Abstract 
Human parvovirus B19 (B19V) infection is highly restricted to human erythroid progenitors. In 
this study, firstly, we have shown that erythroid progenitor cells ex vivo expanded from CD34+ 
hematopoietic cells (HSCs) in the absence of erythropoietin (Epo) [CD36+/Epo(-) EPCs)] did not 
support B19V replication, even though B19V did enter these cells. Epo exposure either prior to 
infection or after virus entry tuned the CD36+/Epo(-) EPCs to accommodate active B19V 
replication. Secondly, a Janus kinase 2 (Jak2) inhibitor, AG490, inhibited phosphorylation of 
Jak2 and thereafter phosphorylation of Epo receptor (EpoR), and subsequently abolished 
replication of B19V in ex vivo expanded erythroid progenitor cells in the presence of Epo 
(CD36+/Epo+ EPCs), at a final concentration of 5 µM. Moreover, expression of a constitutively 
active EpoR in CD36+/Epo(-) EPCs conferred an efficient B19V replication. Finally, we provide 
evidence that B19V replication in CD36+/Epo+ EPCs required Epo in a dose-dependent manner. 
In conclusion, we have demonstrated that the EpoR signaling is absolutely required for B19V 
infection of ex vivo expanded erythroid progenitor cells after initial virus entry, which in part 
explains the remarkable tropism of B19V infection to human erythroid progenitors.         
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Introduction 
 Parvovirus B19 (B19V) is pathogenic to humans. It is an autonomously replicating virus with a 
remarkable tropism to human erythroid progenitors of bone marrow (163, 199). Clinical 
manifestations of B19V infection vary among different health conditions. The most common one 
is erythema infectiosum. However, B19V infection often results in bone marrow failure in the 
following conditions. In patients with increased destruction of erythrocytes and a high turnover of 
erythrocytes (e.g., sickle cell disease patients), acute B19V infection can cause transient 
aplastic crisis. In immunocompromised patients, persistent B19V infection may develop 
manifestations as pure red-cell aplasia, a chronic anemia. B19V fetal infection, however, can 
cause severe anemia in fetus, resulting in non-immune hydrops fetalis and fetal death (2, 57).   
Erythropoiesis is the process whereby a fraction of primitive multipotent hematopoietic stem 
cells (CD34+) commit to the erythroid lineage, forming burst-forming units-erythroid (BFU-Es, 
earlier erythroid progenitors), colony-forming units-erythroid (CFU-Es, later erythroid 
progenitors), normoblasts, erythroblasts, reticulocytes, and ultimately the mature erythrocytes. 
B19V infection shows a remarkable tropism to human erythroid progenitors with the CD36+ 
marker of both BFU-Es and CFU-Es (163, 199). Clinical manifestations of B19V infection, as 
seen in aplastic crisis and pure red-cell aplasia, are due to the direct cytotoxicity of the virus 
infection (29), a direct outcome of the cell death of erythroid progenitors that are targets of B19V 
replication. A progressive host cell apoptosis has been observed during B19V infection of 
primary erythroid progenitor cells (195, 225), which is likely induced by the abundantly 
expressed 11kDa non-structural protein during infection (38). Erythroid progenitors in the 
tissues of fetuses who exhibited hydrops fetalis caused by B19V infection also were 
characteristic of apoptotic cell death (225).  
 Polyadenylation at the proximal site in the center of the B19V genome [(pA)p] precludes the 
inclusion of the capsid-coding open reading frame, and so alternative polyadenylation plays a 
key role in B19V capsid protein production (160, 226). We have recently shown that replication 
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of the B19V genome enhances read-through of the proximal polyadenylation site and the 
polyadenylation of B19V transcripts at the distal site. Therefore, replication of the B19V genome 
facilitates the generation of sufficient full-length transcripts to encode the viral capsid proteins 
(79).  
The remarkable tropism of B19V to human erythroid progenitors was believed to be due to the 
blood-group P antigen (Globoside), the cellular receptor for B19V (28). However, the recent 
finding of co-receptors (138, 218) suggests that erythrocyte P antigen is necessary, but not 
sufficient, for B19V binding and entry; the expression level of the P antigen does not correlate 
with the efficiency of viral binding (219). In addition to the native target cells for B19V infection in 
human bone marrow and fetal livers, a few cell lines (basically myeloblastoid cell line like 
UT7/Epo-S1 (135) and KU812Ep6 (127)) do support B19V replication but in a limited efficiency 
(23, 222). Recently, ex vivo expanded CD36+ erythroid progenitor cells (CD36+ EPCs) have 
been proven to be highly permissive to B19V infection and support active B19V replication (at 
least 100-fold increase of the B19V genome) (195, 206). All the myeloblastoid cell line cells and 
primary CD36+ EPCs require Epo to sustain proliferation, suggesting that Epo is required for 
B19V infection. Epo has been confirmed to be required for susceptibility of human bone marrow 
cells to B19V infection (206), from which a conclusion was drawn that the target cells of B19V 
are in erythroid lineage from BFU-Es to erythroblasts, with susceptibility to B19V increasing 
along differentiation (206). Thus, the role of Epo in B19V permissiveness was thought mainly to 
differentiate bone marrow hematopoietic stem cells (HSCs) to the stage of erythroid progenitor. 
In this study, we have shown a direct role of Epo and its pathway in supporting replication of the 
B19V genome. We prepared CD36+ EPCs by ex vivo expanding CD34+   HSCs in two 
formulated media with or without Epo. In the absence of Epo, the CD36+ EPCs expanded in 
StemCell medium (Tab. 4-1), namely CD36+/Epo(-) EPCs, were not permissive to B19V 
infection, though the virus entered the cells. However, upon addition of Epo either prior to or 
after virus infection, Epo-pulsed CD36+/Epo(-) EPCs became permissive to B19V replication. 
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Moreover, inhibiting EpoR signaling, either by the Jak2 inhibitor AG490 or Jak2 shRNA, 
decreased B19V replication in CD36+ EPCs expanded in Wong medium (Tab. 4-1) with Epo 
(CD36+/Epo+ EPCs). More importantly, expression of a constitutively active EpoR in 
CD36+/Epo(-) EPCs rescued B19V replication to a level comparable to that in CD36+/Epo+ 
EPCs. Thus, our study elucidates an indispensible role of Epo and its pathway in B19V 
replication, which was not appreciated previously, and can partially illuminate why B19V prefers 
to propagate in cells which take Epo as an essence to proliferate.                 
  
 
Materials and Methods 
Generation of CD36+ EPCs: CD34+ HSCs were purchased from National Disease Research 
Interchange (NDRI), Philadelphia, PA. One million cells were cultured in two different expansion 
media as described in Table 4-1. CD34+ HSCs were ex vivo expanded in Wong medium from 
day 0 and stored in liquid nitrogen at day 4 as described previously (14,45). Large numbers of 
CD36+ EPCs were expanded in StemCell medium continuously until day 6 or day 8 for 
purification, and day 8 for B19V infection where indicated. 
 
Construction and production of retroviral and lentiviral vectors:  
 Retroviral vector expressing Epo-R(R129C): Plasmid pMSCV-EpoR(R129C)-IRES-GFP was 
constructed by inserting EpoR(R129C) gene (13) into BamH-Xba-digested pMSCV-MCS-IRES-
GFP-WRE vector. Retroviruses (Retro-EpoR and Retro-GFP) were produced by transfecting 
pMSCV-EpoR(R129C)-IRES-GFP and pMSCV-IRES-GFP, respectively, with pCMV-VSVG in 
GP293 cells (Clontech). Concentration of retroviral vectors was carried out following the 
manufacturer’s instructions (Clontech, cat. No.:PT3132-1).  
 Lentiviral vectors expressing shRNA: We obtained pLKO.1 cloning vector and pLKO-
Scrambe-shRNA vector from Addgene Inc. (Cambridge, MA). The puromycin resistance gene in 
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pLKO vectors was replaced by the GFP ORF from pC1GFP (Clontech) through BamHI/KpnI 
sites, resulting in pLKO-GFP and pLKO-GFP-Scramble-shRNA, respectively. The validated 
JAK2 shRNA1 sequence (TRCN0000003181, NM_004972, Sigma) was cloned into pLKO-GFP 
through AgeI and EcoRI sites, which resulted in pLKO-GFP-Jak2-shRNA. Lentivirus was 
generated and concentrated following Addgene’s instructions (http://www.addgene.org/plko).  
         
Purification of CD36+ EPCs cultured in StemCell medium: 3× 106 of CD34+ HSCs were 
cultured in StemCell medium. At day 6 or 8, approximately 2-3 × 107 expanded cells were spun 
down at 300 g for 10 min, resuspended in 1 ml of autoMACS rinsing buffer (Miltenyi Biotec, 
Auburn, CA), and incubated with mouse anti-human CD36 antibody (BD Biosciences, 106 
cells/μl) for 15 min at 4 °C. Then cells were spun down at 2, 250 rpm for 2 min and washed 
three times with the autoMACS rinsing buffer. After incubation with anti-mouse IgM magnetic 
microbeads (Miltenyi Biotec) for 15 min at 4 °C, cells were loaded onto MS column and labeled 
cells were eluted following the manufacturer’s instructions. Purified CD36+ EPCs expanded in 
the absence of Epo were named as CD36+/Epo(-) EPCs.  
 
Virus and infection:    
We obtained B19V viremic plasma samples, P20 (14) and P32, from ViraCor Laboratories 
(Lee's Summit, MO), and quantified for B19V genomic copies [1012 genomic copies (gc)/ml] as 
previously described (14). Infection was performed at a multiplicity of infection (MOI) of 5,000 
genomic copies (gc)/cell [approximately 1 fluorescent foci-forming unit (fffu)/cell]. Except for Fig. 
4-1, for which P20 was used, all other figures were generated by using P32 for consistency.        
For retroviral transduction, concentrated retrovirus was added to CD36+/Epo(-) EPCs purified at 
day 6 of culture at an MOI of 4 fffu/cell. B19V infection was carried out at 48 hrs 
posttransduction (p.t.).   
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Viral entry assay and replication quantification: For Viral entry assay (2), cells were infected 
with B19V at an MOI of 5,000 gc/cell. At 2 hrs after incubation with the virus, the cells were 
washed with AMEM (Alpha Modification of Eagles Medium, Mediatech, Manassas, VA), and 
spun down at 2,200 rpm for 3 min. The cell pellet was then resuspended in 0.5 million cells per 
100 μl of trypsin/versene (0.25% trypin in 20mM EDTA buffer) for 5 min at 37 ºC. Total DNA 
was extracted following instructions of the Blood DNA Mini Kit (Qiagen) with modification. 
Extracted DNA was then used to quantify B19V genomic copies by quantitative real time PCR 
(qPCR) as described previously (15). The replicated B19V genome was extracted as described 
above and quantified by qPCR at 48 hrs p.i., except Fig. 4-3C at 24 hrs p.i. 
Southern blot analysis: At 48 hrs p.i., cells were harvested for Hirt DNA extraction, and Hirt 
DNA samples were analyzed by Southern blot as described previously (14,15). Blots were 
exposed to a GE phosphor imaging screen, and quantified by a phosphor imager (Storm 856) 
using Image Quant TL software v2005 (GE Healthcare). 
 
Reverse transcription (RT) and quantitative real time PCR (RT-qPCR): We extracted mRNA 
using TurboCapture mRNA kit (Qiagen) following manufacturer’s instructions. We then 
performed reverse transcription directly in the TurboCapture tubes using random hexamers 
(Promega) and MMLV-RT (Invitrogen). A multiplex RT-qPCR was performed to detect B19V 
VP2-encoding mRNA and B19V mRNA spliced from D1 donor site to A1-2 acceptor site (D1/A1-
2-spliced mRNA) (14), with β-actin mRNA serving as an internal control as previously reported 
(14,15).   
 
Immunofluorescence: Infected cells were cytocentrifuged at 1, 500 rpm for 5 min and fixed in 
a mixture of acetone and methanol (1:1) at - 20°C for 15 min. The staining was performed as 
previously described using anti-B19V capsid (clone 521-5D) and FITC- conjugated anti-mouse 
IgG (15).  
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Western blot analysis: Cell lysates were prepared at 48 hrs post-treatment, and used for 
Western blotting analysis as previously described (34).   
 
Cell viability assay: We examined cell viability using CellTiter-Glo® kit (Promega) to determine 
the number of viable cells in culture based on quantifying the ATP presence following 
manufacturer’s instructions.   
 
Flow cytometry analysis:   
For surface staining, 105 cells were incubated with the first antibody at 1: 100 dilution in a 
volume of 100 µl of PBS containing 2% FCS (PBS-FCS) for 30 min at room temperature (RT). 
Washed twice with PBS-FCS, cells were incubated with FITC-conjugated secondary antibody at 
a dilution of 1: 100 for 30 min at RT. After washing, the cells were fixed in 1% paraformaldehyde 
before analysis. The intracellular staining was basically performed as previously described (7).  
   
Results 
CD36+ EPCs differentiated from CD34+ HSCs in the absence of Epo are not permissive to 
B19V infection.   
To distinguish the role of Epo in differentiating HSCs and supporting B19V replication, we 
generated erythroid progenitor cells, which possess erythroid progenitor marker CD36 (60, 154) 
through differentiating human bone marrow derived-HSCs (CD34+ cells) in two expansion media. 
They contain different combination of cytokines as described in Tab. 4-1.   
 At day 8 in culture, cells in different expansion media were analyzed by flow cytometry 
with antibodies to erythroid markers (CD36, GPA, EpoR, and CD71), B19V receptor (Globoside) 
and co-receptors (CD49e and KU80), and the CD41 megakaryoblastic marker (214) as well as 
the CD34 HSC marker for specific lineage differentiation of the cells. The ex vivo expanded cells 
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both in Wong and StemCell media expressed CD36 marker at 99.4% and 41.5%, respectively 
(Fig. 4-1A). Expanded cells in StemCell medium (without Epo) retained a considerable level of 
CD34 maker at 23.3%, and a low level of CD41 marker at 7.4% (Fig. 4-1A), indicating their 
lineage differentiation toward erythroid progenitor cells. CD71, the transferrin receptor, was 
expressed at levels of 96.8%  
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Table 4-1. Formula of expansion media for CD36+ EPCs.  
Serum-free expansion media (SFEM) and BIT9500 (BIT) were obtained from StemCell 
Technologies Inc. (Vancouver, BC, Canada). All the cytokines were purchased from Invitrogen 
except for the Epo from Amgen. SCF=Stem cell factor; IL-6=Interleukin 6; IL-3=Interleukin 3; Flt-
3-L=Flt-3 ligand; TPO=Thrombopoietin; Epo=Erythropoietin. Wong medium also contains 900 
ng/ml of Fe2+, 90 ng/ml of Fe3+ and 1μM of Hydrocortisone as described previously (79, 222).         
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Name of medium StemCell Wong 
Serum-free base: SFEM BIT in AMEM 
Cytokines (ng/ml):   
SCF 100 100 
IL-6 20 x 
IL-3 20 5 
Flt-3-L 20 x 
TPO 50 x 
Epo x 3      (unit/ml) 
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Figure 4-1. CD36+ EPCs expanded in StemCell medium without Epo are not permissive to 
B19V infection. 
CD34+ HSCs were cultured in StemCell medium shown in Tabel 1. (A) At day 8 of culture, the 
indicated surface markers of cells from different cultures were analyzed and presented in 
histogram. For surface staining, antibodies against cell surface antigen CD34, CD36, CD41, 
GPA, CD71 and CD49e (all obtained from BD Biosciences, San Jose, CA), and antibodies 
against globoside (Matreya, Pleasant Gap, PA), KU80 (Calbiochem, San Diego, CA) and EpoR 
(Abcam, Cambridge, MA) were used to characterize cell phenotype. Numbers in each panel 
indicate the percentage of positive population. A representative result from two independent 
experiments is shown. (B) At day 8 of culture, B19V infection was carried out as described in 
Materials and Methods. Immunofluorescence staining was performed at 48 hrs p.i. using 
antibody against B19V capsid antibody. DAPI was used to stain nucleus. Images were acquired 
by an Eclipse C1 Plus confocal microscope (Nikon) at a magnification of x 40. 
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and 16.7% (Fig. 4-1A), respectively, on cells expanded in Wong and StemCell media. Cells 
gained the GPA (CD235a) marker at a high extent, 97.2%, on CD36+ EPCs expanded in Wong 
medium, while only 30.0% on cells expanded in StemCell medium (Fig. 4-1A). Cells expanded 
in both media expressed a high level of globoside and CD49e, the primary receptor and co-
receptor for B19V infection (4,44), as well as the EpoR (Fig. 4-1A). Interestingly, KU80, which 
was proposed as a co-receptor of B19V (24), was expressed on the most of cells (65.3%) 
expanded in StemCell medium, but only on 4.6% of the cells expanded in Wong medium (Fig. 
4-1A).   
 We then infected these two types of CD36+ EPCs with B19V in their respective media for 
two days. B19V infectivity was examined by immunofluorenscence with anti-B19V capsid 
antibody (Fig. 4-1B). Surprisingly, CD36+ EPCs expanded in StemCell medium, which did not 
contain Epo, were not permissive to B19V infection as shown by negative anti-capsid staining. 
Conversely, CD36+ EPCs expanded in Wong medium, which contained Epo at 3 units/ml, 
showed more than 80% of cells positive with anti-capsid staining, indicating an effective 
infection (222). This result suggests that the committed erythroid progenitor cells cultured in the 
absence of Epo are not permissive to B19V infection, and Epo is required not only for 
differentiation of erythroid progenitor cells but also may be necessary for B19V infection of 
erythroid progenitor cells.   
 
Epo confers permissiveness of B19V infection to CD36+/Epo(-) EPCs by turning on viral 
genome replication. 
We next chose to purify CD36+ EPCs from the cells expanded in StemCell medium. Purified 
cells, named as CD36+/Epo(-) EPCs, were analyzed by flow cytometry, expressing uniform 
erythroid progenitor markers, i.e., CD36+ at 87.5%, GPA+ at 88.2% and EpoR+ at 84.5%, as well 
as high levels of B19V receptor (Globoside+ at 87.9%) and co-receptors (CD49e+ at 39.4% and 
KU80+ at 85.7%). Interestingly, these purified cells were mostly (82.5%) both CD34+ and CD36+ 
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(Fig. 4-2B, 0 hr), indicating they were at the stage of BFU-E (154). Similar to unpurified cells 
expanded in StemCell medium (Fig. 4-1B), purified CD36+/Epo(-) EPCs were not susceptible to 
B19V infection as shown by negative anti-capsid staining and undetectable B19V mRNAs (Fig. 
4-2C, D&E). 
To examine whether Epo is absolutely required for B19V infection, we pretreated purified 
CD36+/Epo(-) EPCs with Epo at 3 unit/ml for 2 hrs and overnight (approximately 16 hrs), 
respectively, followed by B19V infection. Interestingly, cells treated with Epo for 2 hrs or 
overnight clearly became susceptible to B19V infection to some extent (Fig. 4-2C, D&E). With 
overnight Epo treatment, approximately 10% of purified CD36+/Epo(-) EPCs expressed B19V 
capsid, as well as B19V VP2-encoding mRNA (at a level of 0.7% of β-actin mRNA copy) and 
D1/A1-2-spliced mRNA (at a level of 0.4% of β-actin mRNA copy), respectively. As 
demonstrated by virus entry assay and DNA replication quantification, while purified 
CD36+/Epo(-) EPCs without Epo treatment did not show any increase of the B19V genome, Epo 
treatment for 2 hrs and overnight facilitated replication of the B19V genome for approximately 
2.5-fod and 13-fold, respectively (Fig. 4-3A). As control, CD36+/Epo+ EPCs supported 
approximately 93-fold increase of entered B19V genome. Interestingly, we also  
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Figure 4-2. Epo pulse confers B19V viral protein expression in CD36+/Epo(-) EPCs. 
Purified CD36+/Epo(-) EPCs were pulsed with Epo (3 U/ml) for different length of time. (A) 
Indicated surface markers were determined on cells with different treatments. (B) Double 
staining of CD34 and CD36 markers on cells with different Epo treatments. (C) Cells were 
treated with Epo as indicated, and infected with B19V. At 48 hrs p.i., immunofluorescence 
staining of B19V capsid was performed with costaining of DAPI to show nucleus. Images were 
acquired by an Eclipse C1 Plus confocal microscope (Nikon) at a magnification of x 40. (D&E) 
At 48 hrs p.i., VP2-encoding mRNA (D) and D1/A1-2-spliced mRNA (E) were quantified by 
multiplex RT-qPCR and presented as copy number per β-actin mRNA (internal control) with 
average and standard deviation as shown.    
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observed that CD36+/Epo+ EPCs allowed B19V entry to the most extent, approximately 17 times 
more than that into purified CD36+/Epo(-) EPCs without Epo treatment, and approximately 5-8 
times more than that into the cells treated with Epo for either 2 hrs or overnight (Fig. 4-3A). This 
indicates that B19V virus entry of CD36+ EPCs is affected by Epo stimulation.   
Cell surface markers on purified CD36+/Epo(-) EPCs treated with Epo for 2 hrs and overnight 
revealed slight shift toward the profile presented on CD36+/Epo+ EPCs, especially the CD34, 
CD41 and CD71 markers (Fig. 4-2A). This result indicates that Epo treatment does differentiate 
the cells from BFU-E- to CFU-E-type cells which loose both CD34 and CD41 markers (154).   
Taken together, we demonstrated that susceptibility of CD36+/Epo(-) EPCs to B19V infection is 
not due to the blockage of viral entry; instead, these cells do not facilitate replication of the B19V 
genome, and Epo treatment turned on B19V replication in these cells. As markers of Epo 
treatment (18), increased levels of phosphorylated Jak2 (pJak2) and phosphorylated Epo 
receptor (pEpoR) were detected in cells treated with Epo for 2 hrs and overnight (Fig. 4-3B) 
compared with cells without Epo treatment. Thus our results suggest that the Epo/EpoR 
signaling is likely essential to B19V replication. 
To rule out the potential interference from viral entry, we performed B19V entry assay prior to 
Epo stimulation. In such a condition, at the time of Epo treatment, the cells in different groups 
have exactly the same amount of entered viral genome. Again, CD36+/Epo+ EPCs  
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Figure 4-3. Epo stimulation is a switch of B19V replication in CD36+/Epo(-) EPCs.  
(A&B) We pulsed purified CD36+/Epo(-) EPCs with Epo (3 U/ml) for different lengths of time 
prior to B19V infection. CD36+/Epo+ EPCs expanded in Wong medium were used as control. (A) 
B19V entry and DNA replication were determined as described in Materials and Methods. The 
number in the panel indicated the fold difference between replication and entry. The “No Epo” 
group bars were enlarged to better present the results with scale. (B) We determined the 
phosphorylation of EpoR and Jak2 by flow cytometry in cells with different treatment 
immediately before B19V infection. We used anti-pEpoR (Tyr 456) (Santa Cruz Biotech, Inc., 
Santa Cruz, CA), anti-pJak2 (Tyr 1007) (Genscript, Piscataway, NJ ) and anti-B19V NS1 (8) for 
staining pJak2, pEpoR and B19V NS1, respectively. We used Cy5-conjugated anti-mouse or 
rabbit secondary antibodies for intracellular staining. Quantification of Mean Fluorescence 
Intensity (MFI) with the reference line indicating the background is shown in bar figures to the 
right in panel B. 
(C, D&E) We recovered purified CD36+/Epo(-) EPCs in StemCell medium for 1 hr, then we 
infected cells with B19V. While one fifth of the cells were used to quantify viral entry, the other 
four-fifths of the cells were evenly divided into four groups for Epo treatment for 0, 2, 8 and 24 
hrs, respectively. CD36+/Epo+ EPCs expanded in Wong medium were used as control. B19V 
entry and replication were quantified by qPCR and presented as B19V genome copy number 
per cell (gc/cell). (C). B19V VP2-encoding mRNA (D) and D1/A1-2-spliced mRNA (E) were 
quantified by RT-qPCR and presented as copy number per β-actin mRNA (internal control).  
Average and standard deviation are shown in panel A, C, D and E, and were calculated from at 
least three independent experiments. 
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were used as control. While no replication was observed at 24 hrs p.i. without Epo stimulation, 
Epo treatment for 2, 8 and 24 hrs increased B19V DNA replication 2.2-, 3.9- and 8.3-fold of 
entered viral genome, respectively (Fig. 4-3C). As control, CD36+/Epo+ EPCs replicated viral 
genome for approximately 11-fold of the entered B19V genome at 24 hrs p.i. In terms of the 
B19V mRNAs, no VP2-encoding mRNA and D1/A1-2-spliced mRNA were detected from 
infected cells without Epo stimulation (Fig. 4-3D&E). Increasing amounts of Epo pulse conferred 
increasingly detectable levels of both VP2-encoding and D1/A1-2-spliced mRNAs from infected 
CD36+/Epo(-) EPCs, though the level was still lower than that in CD36+/Epo(+) EPCs. 
Thus, our results indicate a pivotal role of Epo in B19V replication. Epo is absolutely required to 
turn on replication of B19V genome and thus confers the permissiveness of CD36+/Epo(-) EPCs 
to B19V infection.               
 
Inhibiting phosphorylation of Jak2 blocks B19V replication in CD36+/Epo+ EPCs.  
 Epo ligation triggers EpoR dimerization and in turn phosphorylates Jak2 that is 
associated with EpoR (115). Phosphorylated Jak2 then phosphorylates tyrosine residues in the 
cytoplasmic tail of EpoR. We decided to investigate whether this phosphorylated Jak2 (pJak2)-
mediated Epo/EpoR signaling is involved in facilitating B19V replication. To this end, we used a 
Jak2-specific inhibitor, AG490 (125), to inhibit Jak2 phosphorylation. The inhibitory effect of 
AG490 was examined by detecting pJak2 and phosphorylated EpoR (pEpoR) as shown (Fig. 4-
4A). At 2 and 5 µM, AG490 effectively decreased the phosphorylation of both  
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Figure 4-4. Jak2 inhibitor abolishes B19V replication in CD36+/Epo+ EPCs.  
CD36+/Epo+ EPCs at day 7 were treated with inhibitors at concentrations as indicated. Twenty 
four hours later (day 8), inhibitor-treated cells were infected with B19V. (A) At 48 hrs post-
treatment, a part of the cells were harvested and analyzed by Western blot using antibodies as 
indicated. Quantification of bands on blots is shown as relative levels to DMSO control (0.5% 
DMSO). (B) The cytotoxicity of inhibitor treatment was evaluated using CellTiter-Glo® kit at 48 
hrs post-treatment. The luminescence readings are normalized by the value of cell control group 
(Non-treated). (C) The level of cell death of cells treated with indicated concentrations of AG490 
was evaluated by AnnexinV/PI double staining. The numbers indicate the percentage of cells in 
each gate versus parental population. In the bottom panel, AG490-treated cells were stained 
with DAPI to show the cell cycle pattern. The numbers indicated percentage of cells in G0/G1, S 
and G2/M phase respectively. (D) At 48 hrs p.i., Hirt DNA was extracted from infected cells and 
analyzed by Southern Blot. Double replication form (dRF), replication form (RF) and single-
stranded DNA (ssDNA) of B19V are indicated. At 48 hrs p.i., mRNAs encoding VP2 (E) and 
spiced from D1 to A1-2 sites (F) were quantified by RT-qPCR and presented as copy number 
per β-actin mRNA (as internal control). (G) B19V entry and replication were quantified by qPCR 
as described in Materials and Methods and presented as B19V genome copy number per cell. 
Average and standard deviation are shown in panel A, B, D, E and F were calculated from at 
least three independent experiments.  
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Jak2 and EpoR in a dose-dependent manner. Particularly, at 5 µM, pJak2 and pEpoR were 
decreased to approximately 20% and 30% of those in the DMSO control, respectively. The 
cytotoxicity of AG490 in CD36+/Epo+ EPCs was monitored by using the Titer-Glo™ kit, 
AnnexinV/PI and DAPI staining (Fig. 4-4B&C). No significant retardation of cell viability was 
observed at either concentration. However, at 2 μM, AG490 inhibited B19V infection significantly 
with a decrease of approximately 20-fold in B19V DNA replication as shown by Southern blot 
analysis (Fig. 4-4D, lane 3 vs. 2) as well as expression of B19V VP2-encodig mRNA and D1/A1-
2-spliced mRNA (Fig. 4-4E&F). Strikingly, using AG490 at 5 μM, both B19V DNA replication and 
expression of VP2-encoding and D1/A1-2-spliced mRNAs were undetectable (Fig. 4-4D, lane 4, 
and Fig. 4-4E, F&G), indicating that B19V infection of CD36+/Epo+ EPCs is sensitive to AG490 
treatment. As control, AG490 treatment did not affect B19V entry to the cells (Fig. 4-4G).  
To confirm the role of Jak2, we next sought to use Jak2-specifc shRNA to knock down Jak2 
expression. We generated a lentivirus expressing shRNA to Jak2 (Lenti-GFP-Jak2-shRNA) and 
a lentivirus expressing scramble shRNA (Lenti-GFP-Scramble-shRNA). CD36+/Epo+ EPCs 
were pretreated with lentiviruses two days prior to B19V infection. At 2 days p.i., GFP-
expressing cells were gated and analyzed by flow cytometry using anti-Jak2 and anti-B19V NS1 
staining. In agreement with the decreased level of Jak2, approximately 50% knock-down, in 
GFP-Jak2-shRNA-expressing cells, the level of anti-B19V NS1 was significantly decreased 
approximately 50%, compared to that in GFP-Scramble-shRNA-expressing cells (Fig. 4-5A). 
Replication of the B19V genome, as  
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Figure 4-5. Jak2 shRNA reduces B19V infection of CD36+/Epo+ EPCs.  
CD36+/Epo+ EPCs at day 6 were transduced with Lenti-GFP-Jak2-shRNA and Lenti-GFP-
Scramble-shRNA, respectively. At 48 hrs p.t., transduced cells were infected with B19V. (A) At 
48 hrs p.i., cells were harvested and stained intracellularly for antigen as indicated. GFP-
expressing cells were selectively gated to quantify expression levels of Jak2 and B19V NS1. 
The percentage of B19V NS1-expressing cells in each group is shown in the histograms, and 
the MFI of Jak2 expression was quantified and presented in the bar figure to the right in panel A. 
(B&C) At 48 hrs p.i., cells were harvested for mRNA isolation using the Turbo mRNA kit as 
described in section Materials and Methods. RT-qPCR was carried out to determine B19V VP2-
encoding mRNA/β-actin mRNA (B) and B19V D1/A1-2-spliced mRNA/β-actin mRNA (C). 
Average and standard deviation are shown in panel B and C, and were calculated from at least 
three independent experiments. 
116 
 
117 
 
assayed by the levels of B19V VP2-encoding mRNA and D1/A1-2-spliced mRNA, decreased by 
approximately 3-fold in cells expressing GFP-Jak2-shRNA (Fig. 4-5B&C), confirming the 
important role of Jak2 in facilitating B19V infection of CD36+/Epo+ EPCs.  
 Taken together, these results indicate that the Epo/EpoR/pJak2/pEpoR signaling 
pathway is crucial in facilitating B19V infection of CD36+/Epo+ EPCs. 
 
Expression of constitutively active EpoR activates B19V infection of CD36+/Epo(-) EPCs.  
 To further confirm the role of EpoR signaling pathway during B19V infection, we 
generated a retroviral vector that expresses a constitutively active EpoR gene (75). Purified 
CD36+/Epo(-) EPCs were transduced with Retro-EpoR or Retro-GFP (as control) 48 hrs prior to 
B19V infection. At 48 hrs p.i., GFP-expressing cells (approximately 50%) were gated and 
analyzed by flow cytometry using intracellular staining of anti-pEpoR, anti-pJak2 and anti-B19V 
NS1 antibodies, respectively. Retro-EpoR-transduced cells successfully expressed 
constitutively activated Epo-R, as shown by an increased level of anti-pEpoR staining, which 
presumably was phosphorylated by the active Jak2 as detected, compared to those staining in 
Retro-GFP-transduced cells (Fig. 4-6A). Correspondingly, Retro-EpoR-transduced cells showed 
a higher level of anti-B19V NS1 staining by approximately 40%, compared to nearly negative 
staining of anti-B19V NS1 (1.1%) in Retro-GFP-transduced cells (Fig. 4-6A). Levels of B19V 
mRNAs and replication of the B19V  
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Figure 4-6. Retroviral transduction of constitutively active EpoR confers CD36+/Epo(-) 
EPCs permissive to B19V infection.    
Purified CD36+/Epo(-) EPCs were transduced with GFP control retrovirus (Retro-GFP) and 
constitutively active EpoR-expressing retrovirus (Retro-EpoR). At 48 hrs p.t., cells were infected 
with B19V. (A) At 48 hrs p.i., infected cells were harvested and stained intracellularly for 
antigens as indicated. GFP-expressing cells were selectively gated to quantify expression levels 
of pJak2, pEpoR and B19V NS1. The percentage of B19V NS1-expressing cells is shown in 
histograms. The MFI of pEpoR and pJak2 expression was quantified and presented in the bar 
figure to the right in panel A. (B&C) At 48 hrs p.i., cells were harvested for mRNA isolation. RT-
qPCR was carried out to determine B19V VP2-encoding mRNA/β-actin mRNA (B) and B19V 
D1/A1-2-spliced mRNA/β-actin mRNA (C), respectively. (D) B19V entry and genome replication 
levels in cells with indicated treatment were quantified by qPCR and presented as genomic copy 
number per cell (gc/cell). Fold changes between replication and virus entry are shown. The bars 
of “Retro-GFP” group are enlarged to scale for better presentation. Average and standard 
deviation are shown in panel B, C and D, and were calculated from at least three independent 
experiments. (E) Several key cell surface markers of erythroid progenitors were stained as 
indicated at 48 hrs p.t., prior to B19V infection. GFP-expressing cells were selectively gated in 
Retro-GFP and Retro-EpoR groups, respectively. Cy5-conjugated secondary antibodies were 
used for flow cytometry analysis to generate this panel. A representative result from two 
independent experiments is shown.  
Two groups of cells, CD36+/Epo(-) EPCs treated with Epo overnight (Epo o/n) and CD36+/Epo+ 
EPCs, were set up as controls.   
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genome were further confirmed to be significantly high in Retro-EpoR-transduced cells, but 
were not detectable in the control Retro-GFP-transduced cells (Fig. 4-6B, C&D).  
 Expression of a constitutively active EpoR differentiated transduced cells in erythroid 
lineage toward CD36+/Epo+ EPCs as shown by the profile of these major cell surface markers, 
which typically include the decreased level of CD34 and increased levels of GPA and CD71 (Fig. 
4-6E). In consistence, B19V entry was increased approximately 6.2-fold in Retro-EpoR-
transduced cells; however, B19V genome in these cells was replicated by approximately 86-fold 
(Fig. 4-6D), suggesting that expression of the constitutively active EpoR accommodates 
replication of the B19V genome. Thus, we have provided direct evidence that expression of the 
constitutively active EpoR renders B19V-nonpermisisve CD36+/Epo(-) EPCs to be permissive, 
confirming the role of EpoR/Jak2 signaling in B19V infection of erythroid progenitor cells.    
 
B19V infection of CD36+/Epo+ EPCs responds to Epo concentration.  
We next sought to confirm the role of Epo in B19V infection of CD36+/Epo+ EPCs expanded in 
Wong medium. To this end, we cultured cells from day 4 stock in Wong medium but with various 
concentrations of Epo. These cells were infected at day 8 and analyzed at 48 hrs p.i. We found 
that, with the increase of Epo concentration from 0.1, 0.5 to 2 U/ml, NS1-expressing cells were 
increased from approximately 12, 30 to 50% as determined by flow cytometry using anti-NS1 
staining (Fig. 4-7A). No significant difference was observed in groups with 2 and 10 U/ml of Epo. 
Consequently, phosphorylation of both EpoR and Jak2  
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Figure 4-7. B19V infection of CD36+/Epo+ EPCs responds to the Epo concentration in 
culture.  
CD34+ HSCs were ex vivo expanded in Wong expansion medium from day 0 and stored at day 
4. From day 4 stock in liquid nitrogen, thawed cells were cultured in Wong medium containing 
Epo at concentrations as indicated until day 8 when B19V infection was carried out. (A) At 48 
hrs p.i., cells were harvested and stained for antigens intracellularly as indicated. The 
percentage of B19V NS1-expressing cells is shown. MFI of the anti-pEpoR and anti-pJak2 
staining was quantified and is presented in the bar figures to the right in panel A. (B&C) At 48 
hrs p.i., cells were harvested for mRNA isolation. RT-qPCR was carried out to determine the 
level of B19V VP2-encoding mRNA per β-actin mRNA (B) and the level of B19V D1/A1-2-
spliced mRNA per β-actin mRNA (C), respectively. (D) At 48 hrs p.i., total DNA was extracted 
from infected cells. The B19V genomic copy numbers in each group were determined and 
expressed as gc/cell. Levels of virus entry were determined as described in Materials and 
Methods, and fold changes between replication and virus entry are shown. Average and 
standard deviation are shown in panel B, C and D, and were calculated from at least three 
independent experiments. 
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was increased proportionally in groups with Epo from 0.1 to 0.5 and 2 U/ml, but remained at a 
similar level between groups with Epo of 2 and 10 U/ml (Fig. 4-7A). In addition, we observed an 
increase of B19V infection in these groups with Epo from 0.1 to 0.5 and 2 U/ml as confirmed by 
the levels of B19V VP2-encoding mRNA, D1/A1-2-spliced mRNA, and B19V DNA replication 
(Fig. 4-7B, C&D). However, B19V virus entry to cells in all groups with different Epo 
concentrations was determined to be similar (Fig. 4-7D). Collectively, we have shown that the 
level of B19V infection in CD36+/Epo+ EPCs is dependent on Epo concentration, again 
confirming the role of Epo in B19V replication.   
 
Discussion 
B19V is highly tropic to human erythroid progenitor cells, which was previously thought to be 
simply due to the presence of the P antigen (Globoside), the B19V receptor (28). We have 
recently demonstrated that replication of B19V genome is a limiting step during B19V infection 
of erythroid progenitors (79). Expression of B19V capsid-encoding mRNA requires reading 
through the proximal polyadenylation site, which is affiliated by replication of the genome. In this 
study, we provide strong evidence showing that the EpoR signaling pathway is important for 
B19V replication in erythroid progenitor cells. Our study thus further supports the hypothesis 
that the limiting step of B19V infection is the replication of the B19V genome rather than the 
virus entry.  
Erythropoiesis and B19V infection: Previous study has shown that Epo is essential to 
differentiate human hematopoietic stem cells to be susceptible to B19V (206). But the role of 
Epo in B19V infection was thought to be only for directing differentiation of the hematopoietic 
stem cells to erythroid progenitor cells at the stages of BFU-E, CFU-E and erythroblasts (206).  
Erythropoiesis is a regulated process whereby hematopoietic progenitor cells give rise to 
committed erythroid progenitor cells, differentiate and proliferate to mature red blood cells. It 
includes the Epo-independent early phase of erythropoiesis, the commitment of pluripotent 
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hematopoietic stem cells to erythroid lineage, and the Epo-dependent late phase that facilitates 
terminal maturation of precursors into circulation enucleated erythrocytes. The commitment of 
hematopoietic stem cells to both early and late erythroid progenitors (BFU-E and CFU-E) is 
independent of Epo (152, 164, 223, 224). Stem cell factor (SCF) (55, 140, 164, 224), interleukin-
6 (IL-6) (202) and IL-3 (164) have been reported to stimulate early erythropoiesis or generation 
of erythroid progenitors. In contrast, Epo is a late-acting factor of erythropoiesis, which is 
erythroid-lineage-specific and supports proliferation and maturation of committed erythroid 
progenitors (152). Epo acts on committed erythroid progenitors to stimulate the later phase of 
erythroid differentiation (106). Interestingly, Epo-independent erythrocyte production also has 
been reported (202).  
In this study, we used key markers of erythroid progenitors (70), i.e., CD36, CD71, EpoR and 
GPA, and B19V receptors to profile CD36+ EPCs expanded in media with or without Epo. CD36 
is detected early on erythroid progenitors, and has been used to monitor hematopoietic 
differentiation (60, 69, 142, 154). EpoR is the cellular receptor for Epo presented on erythroid 
progenitors; it appears on erythroid progenitors at BFU-E stage and highly expresses on the 
most Epo-sensitive CFU-Es (70). Similar to EpoR, CD71, transferrin receptor, is expressed on 
cells at the BFU-E stage and disappears at late reticulocyte stage (69, 154). GPA is a specific 
membrane component of mature erythrocytes. GPA is expressed on cells from erythroid 
progenitors at CFU-E stage (116) to proerythroblast (55, 69, 154, 194). CD41 is a cell surface 
marker for megakaryocyte, and is not present on erythroid progenitors (154). As judged by 
these key markers of erythroid progenitors, the cells expanded on day 8 in Wong medium were 
basically CFU-E-type cells. Using StemCell medium, we obtained highly pure CD36+ /Epo(-) 
EPCs by stimulating CD34+ HSCs with SCF, IL3, IL6, Flt-3 and TPO. Purified CD36+/Epo(-) 
EPCs process a marker of CD36+87.5% GPA+88.2%EpoR+84.5%, which have no significant difference 
from that of CD36+/Epo+ EPCs expanded in Wong medium (CD36+97.5%GPA+97.2%EpoR+90.3%); 
however, the majority of CD36+/Epo(-) EPCs retain CD34 marker. BFU-Es contain CD34 marker 
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(154), and are devoid of CD71 (92, 205), indicating that the CD36+/Epo(-) EPCs are presumably 
at BFU-E stage. However, these erythroid progenitor cells are sensitive to Epo stimulation, 
which confers their permissiveness to B19V replication.      
P-antigen (Globoside), a glycosphingolipid found on erythroid cells, is a cellular receptor for 
B19V (4). CD49e and KU80 have been reported to be co-receptors of B19V infection (24,44). 
Interestingly, CD36+/Epo+ EPCs expanded in Wong medium allow B19V to enter cells at a high 
efficiency, approximately 17 times higher than that of the CD36+/Epo(-) EPCs. This could be 
due to the increasing expression of CD49e, the co-receptor of B19V (44), or as yet unidentified 
co-receptors, but may not be the KU80 (24). The mechanism by which B19V enters cells 
warrants further investigation. Nevertheless, without Epo stimulation, entered B19V genomes 
did not replicate. We believe that the blockage of B19V infection of CD36+/Epo(-) EPCs is most 
likely at the step of B19V DNA replication, rather than intracellular trafficking of the entered viral 
genomes to the nucleus. Together with our previous finding that expression of adenovirus 
genes confers replication of B19V genome in B19V-nonpermisisve 293 cells (80), we 
hypothesize that replication of the B19V genome requires a unique microenviroment in nucleus, 
which is created upon Epo stimulation in erythroid progenitor cells.     
 
Epo/EpoR/pJAK2/pEpoR signaling pathway is required for B19V replication: Jak2 plays a 
pivotal role in Epo signal transduction (144, 165). Jak2 associates with EpoR at a membrane 
proximal region of the cytoplasmic domain. It is hypothesized that binding Epo to EpoR induces 
a conformational alternation of the EpoR cytoplasmic domain, and allows the juxtaposition of 
Jak2 molecules in a manner that facilitates their transphosphorylation within the activation loop, 
resulting in activation of the Jak2. Upon activation, Jak2 phosphorylates 8 tyrosine residues in 
the cytoplasmic domain of EpoR as well as a number of additional sites on itself (115). 
Phosphorylated EpoR further recruits and mediates activation of SH2-bidning factors including 
STAT5, Grb2 and PI3K, which signal Jak2/STAT5, Ras/MARK and PI3K/AKT pathways. 
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Activating these pathways synergistically prevents apoptosis of committed erythroid progenitors, 
allowing them to undergo a predetermined program of terminal proliferation and erythroid 
differentiation. We have shown here that inhibition of Jak2 kinase and thereafter EpoR 
phosphorylation abolished B19V replication of infected erythroid progenitor cells. Together with 
the Jak2 shRNA experiment, we believe that signaling transduction pathways under the 
Jak2/pEpoR must be involved in B19V replication, which function individually or synergistically. 
In fact, STAT5A, a downstream signaling molecule of Jak2, was observed to be phosphorylated 
at higher level in CD36+/Epo+ EPCs, but not in CD36+/Epo(-) EPCs that have been stimulated 
by cytokines SCF, IL3, IL6, Flt-3 and TPO (data not shown). STAT5 is a transcription activator 
in nucleus that has a profound effect on expression of a set of genes (31), which might be 
required for efficient replication of the B19V genome. Further investigation apparently is 
necessary to understand the mechanism underlying B19V replication of erythroid progenitors.      
Expression of the constitutively active EpoR has been shown to activate Jak2 in condition 
without Epo binding (117). And in our experiment, Jak2 was apparently phosphorylated upon 
expression of the EpoR(R129C) in CD36+/Epo(-) EPCs (Fig. 4-6), and phosphorylated EpoR 
was further regulated by exposing cells with Epo at various concentrations (Fig. 4-7). As a result, 
Retro-EpoR-expressing cells facilitated B19V infection. In agreement, treatment of CD36+/Epo(-) 
EPCs with Epo only for 2 hrs turned on B19V infection of treated cells; while overnight Epo 
treatment conferred treated cells to be infected by B19V at a relatively higher level (Fig. 4-2&3). 
Accordingly, both Jak2 and EpoR are phosphorylated upon Epo treatment. Therefore, our 
results strongly suggest the chain of signal transduction of EpoRactivation of 
Jak2phosphorylation of EpoRB19V replication.  
In conclusion, our study has provided evidence that EpoR signaling is essential to B19V 
replication. Activation of EpoR either by addition of Epo or expressing constitutively active 
EpoR(R129C), confers permissiveness to B19V infection to previously non-permissive but 
committed erythroid progenitors, CD36+/Epo(-) EPCs, by turning on replication of the B19V 
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genome. Conversely, inhibition of Jak2 reduced phosphorylation of EpoR, which in turn 
decreased/blocked B19V DNA replication. Thus, our study reveals a previously unappreciated 
role of EpoR signaling in supporting B19V replication, which can explain the unique tropism of 
B19V infection of human erythroid progenitors.   
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Chapter 5 
Conclusions and Discussion 
 
The studies presented in this thesis for my PhD degree are composed of two parts: 1) 
investigation of the molecular mechanisms underlying the cytopathic effects induced during 
infection of parvovirus B19V and MVC; and 2) identifying the cellular microenvironment that 
facilitates B19V replication. For the first part, we took advantage of a recently developed in vitro 
permissive B19V infection system, and demonstrate that the small nonstructural protein 11kDa 
of B19V is a novel pro-apoptotic protein, which plays a key role in inducing apoptosis during 
B19V infection of erythroid progenitor cells. In contrast, apoptotic cell death during MVC 
infection appears to be viral DNA replication-associated rather than viral protein-induced. In 
addition, a G2/M cell cycle arrest during MVC infection is caused by the viral genome per se 
rather than its replication. For the second part, we demonstrate that Epo/EpoR/Jak2 signaling is 
essential for B19V DNA replication.  
 Virus infection-induced cytopathic effects are often related to disease outcomes, 
particularly in the case of B19V. B19V encodes two small non-structural proteins 11kDa and 
7.5kDa, of which the 11kDa is essential to the viral life cycle. Knocking out the 11kDa protein 
resulted in a significant decrease of  infectious virion production (229). However the precise role 
of 11kDa in B19V infection is unknown. In our study (Chapter 2), we have demonstrated clearly 
that the cytoplasm-localized 11kDa is a novel apoptosis inducer and is expressed abundantly 
during B19V infection of erythroid progenitor cells. It plays a key role in B19V infection-induced 
apoptosis of erythroid progenitor cells (38). Mechanistically, the 11kDa-induced apoptosis is 
mediated by caspase-10, an initiator caspase of the extrinsic apoptosis pathway; and is similar 
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to B19V infection-induced apoptosis. Though caspase-8, the other initiator caspase in the 
extrinsic pathway, was thought to be the ortholog of caspase-10 (22), it could not substitute the 
function of caspase-10 in either B19V- or 11kDa-induced apoptosis. Increasing evidence shows 
that capase-10 and caspase-8, though they sometimes work interchangeably, can function 
differently in other situations (104, 217). Inhibition of 11kDa by antisense oligos during B19V 
infection significantly reduced the level of apoptotic cells as evidenced by decreased TUNEL-
positive cells. Thus, it is reasonable to speculate that the apoptosis induced by 11kDa may be 
important for the release of progeny virus from the nucleus, which warrants further investigation. 
Our continued work on this part shows that the pro-apoptotic activity of 11kDa may reside in the 
C-terminus (Chen AY & Qiu J, unpublished). More experiments are needed to further support 
this observation.  
Our finding of the novel pro-apoptotic activity of 11kDa provides new insights into B19V 
infection-induced cytopathic effects. It “breaks new ground on various fronts, from the basic 
biology of erythroid cells to the mechanisms of B19 parvovirus–induced anemia, and suggests 
an assay that will predict the efficacy of drugs in the treatment of the associated anemia” (126).  
HBoVs are newly emergent parvoviruses that are infectious to humans. They have been 
associated with clinical symptoms, e.g., pneumonia, in children. Without an infectious clone and 
an efficient in vitro culture system, the study of HBoV is difficult (64). MVC belongs to the same 
genus bocavirus as HBoVs and they share high similarity in both genome organization and 
expressed proteins. Thus, we used MVC as a model system to investigate the molecular 
mechanisms underlying bocavirus infection (Chapter 3). Taking advantage of the MVC 
infectious clone and productive culture system established in our lab (204), we examined the 
nature of CPE induced during MVC infection (37). Our results indicate that MVC viral proteins 
do not possess pro-apoptotic activity. Apoptosis induced during MVC infection is tightly 
associated with replication of the viral genome. In contrast to the extrinsic pathway induced 
during B19V infection (caspase-10-mediated), MVC infection triggered an intrinsic apoptosis 
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pathway, as evidenced by Bax translocation and permeabilization of the mitochondrion outer 
membrane. The cell cycle of the host cells was affected by MVC infection, showing an S-phase 
plateau during early stages of infection, which progressed into prolonged G2/M arrest at a later 
stage. The G2/M arrest can be reproduced by transfecting terminal repeats-containing viral 
genomes into host cells. The S-phase plateau, however, only appears when active replication 
takes place. Similarly, expression of HBoV viral proteins individually or together by transfection 
did not induce appreciable levels of cell death or cell cycle arrest (36). Thus our results suggest 
that the DNA replication-associated apoptosis and viral genome-induced cell cycle arrest could 
be a common feature among members in the genus Bocavirus.  
Our work in this part represents the first study looking into the mechanisms underlying 
the cytopathic effect induced during bocavirus infection. It may provide a direct molecular basis 
of bocavirus infection-associated disease. Understanding these mechanisms sheds light on the 
future direction to further delineates the molecular basis of cell cycle arrest and apoptosis 
induced by DNA viruses. Results from other members in our lab have shown that a DNA 
damage response may be one of the bridges connecting viral infection with host cell cycle arrest 
and apoptosis. Active investigation is currently being undertaken in our lab to further understand 
the molecular details.  
Epo has been clearly shown to be essential for the differentiation and proliferation of 
determined erythroid progenitor cells. In Chapter 4, we demonstrate that Epo/EpoR/Jak2 
signaling is also crucial for B19V infection, particularly viral DNA replication. Erythroid progenitor 
cells cultured in Epo-depleted medium were not permissive to B19V unless treated with Epo. 
Using different approaches either to down- or up-regulate EpoR and Jak2, we show that EpoR 
and Jak2 phosphorylation correlated directly with B19V replication. It is worth emphasizing that 
the inhibition of Jak2 by the specific inhibitor AG490, at no/low toxic levels, significantly blocked 
B19V replication. However, the extent of viral entry was not affected. AG490 and its analogs 
could serve as potential candidates for anti-B19V drugs.  
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Our unpublished work indicates that STAT5A, which is activated by Jak2 via 
phosphorylation in erythroid progenitor cells, plays an important role in B19V infection. Knocking 
down STAT5A significantly impaired B19V NS1 expression. STAT5A has been clearly shown to 
play a crucial role in differentiation of erythroid progenitor cells, further supporting the 
importance that the differentiation status of erythroid progenitor cells corresponds to B19V 
permissiveness. In other words, the cellular environment that possesses active differentiation 
potential may also be the condition favoring B19V DNA replication.  
Our work in this part represents the first attempt to explore the Epo/EpoR/Jak2 signaling 
and its role during B19V infection. Our results not only establish a direct connection of the 
Epo/EpoR signaling with B19V DNA replication, but also propose a drug candidate for B19V 
infection. In addition, our findings promote a novel concept that the cellular microenvironment 
determines the exclusive tropism of B19V for erythroid progenitor cells, in addition to the B19V 
receptor and co-receptors (138, 218). It opens up a gate toward deeply understanding how 
cellular signal transduction controls B19V permissiveness. This exact signaling network, which 
we believe to be regulated under Epo/EpoR signaling, is unique to erythroid progenitor cells.  
B19V 11kDa protein interacts with cellular Grb2 via proline-rich SH3-binding motifs (71) 
(Chen AY and Qiu J, unpublished). Grb2 is an important adaptor protein mediating receptor 
(EpoR, in the case of erythroid progenitor cells) triggered Ras-MAPK activation (115). MAPK 
has been implicated in a variety of cellular interactions, including phospholipases, transcription 
factors, and cytoskeletal proteins (151, 185). Our preliminary findings also indicate a crucial role 
of MEK/MAPK in B19V replication (unpublished data). Hence, we speculate that 11kDa 
facilitates B19V progeny virus production via interfering with the MEK/MAPK signaling pathway.   
In conclusion, the work presented in this thesis represents several novel advances in 
understanding the molecular mechanisms underlying parvovirus infection. Those results provide 
molecular-level insights into virus-host interaction during both early and late stages of infection. 
Exploration of cytopathic effects induced during infection shows that distinct mechanisms can 
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be employed effectively by parvoviruses from different genera. In addition, we have introduced a 
novel concept that a unique cellular microenvironment in erythroid progenitor cells is a 
prerequisite to B19V DNA replication, and thus determines the permissiveness to and tropism of 
B19V.  
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